U.S. patent application number 11/583656 was filed with the patent office on 2007-09-13 for systems and methods for arteriotomy localization.
Invention is credited to Thomas Anderson, Charles Emery, Margo Gisselberg, John Kook, Larry Kulesa, Robert Pedersen, David M. Perozek, K. Michael Sekins, Jimin Zhang, Xiao Zhao.
Application Number | 20070213616 11/583656 |
Document ID | / |
Family ID | 37708262 |
Filed Date | 2007-09-13 |
United States Patent
Application |
20070213616 |
Kind Code |
A1 |
Anderson; Thomas ; et
al. |
September 13, 2007 |
Systems and methods for arteriotomy localization
Abstract
A targeting catheter is used to locate an arteriotomy, such as
is formed during a femoral artery catheterization procedure. The
targeting catheter includes one or more targeting aids, such as an
inflatable balloon or sensor (e.g., Doppler or temperature sensor),
to locate the arteriotomy. The targeting aid may be positioned at
the arteriotomy. An ultrasonic beacon on the catheter may then be
located relative to a therapeutic ultrasonic applicator (e.g., by
using acoustic time-of-flight) so that the focus of ultrasonic
energy from the applicator can be aligned with the arteriotomy.
Inventors: |
Anderson; Thomas; (Redmond,
WA) ; Emery; Charles; (Issaquah, WA) ;
Gisselberg; Margo; (Lynnwood, WA) ; Kook; John;
(Seattle, WA) ; Kulesa; Larry; (Bothell, WA)
; Pedersen; Robert; (Woodinville, WA) ; Perozek;
David M.; (Mercer Island, WA) ; Sekins; K.
Michael; (Yarrow Point, WA) ; Zhao; Xiao;
(Redmond, WA) ; Zhang; Jimin; (Bellevue,
WA) |
Correspondence
Address: |
KNOBBE MARTENS OLSON & BEAR LLP
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE
CA
92614
US
|
Family ID: |
37708262 |
Appl. No.: |
11/583656 |
Filed: |
October 19, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60728783 |
Oct 20, 2005 |
|
|
|
60808665 |
May 26, 2006 |
|
|
|
Current U.S.
Class: |
600/448 |
Current CPC
Class: |
A61B 2017/00557
20130101; A61B 5/026 20130101; A61B 8/445 20130101; A61B 2090/397
20160201; A61B 8/0833 20130101; A61B 34/25 20160201; A61B 2090/3929
20160201; A61F 2/82 20130101; A61B 8/4405 20130101; A61B 50/13
20160201; A61B 2090/372 20160201; A61B 2017/00637 20130101; A61M
25/10 20130101; A61B 17/0057 20130101; A61B 8/12 20130101; A61B
8/0841 20130101; A61N 7/02 20130101; A61B 2017/00641 20130101; A61B
18/02 20130101; A61B 2090/3784 20160201; A61B 2090/3958
20160201 |
Class at
Publication: |
600/448 |
International
Class: |
A61B 8/00 20060101
A61B008/00 |
Claims
1. An arteriotomy targeting catheter, comprising: an arteriotomy
targeting aid coupled to the catheter and adapted to detect the
location of an arteriotomy; and one or more beacons coupled to the
catheter proximal to the arteriotomy targeting aid.
2. The catheter of claim 1, wherein the arteriotomy targeting aid
comprises an inflatable balloon.
3. The catheter of claim 2, wherein the balloon comprises an
elastic polymeric material.
4. The catheter of claim 3, wherein the soft elastic polymeric
material is selected from the group consisting of one or more of a
polyamide, a polyamide blend, a polyethylene, a polyethylene
terephthalate, a polyurethane, a polyamide, and a polyamide
blend.
5. The catheter of claim 4, wherein the polyamide blend is
PBAX.
6. The catheter of claim 2, wherein the durometer of the balloon
material is between 20A and 90D.
7. The catheter of claim 6, wherein the durometer of the balloon
material is between 80 A and 65 D.
8. The catheter of claim 7, wherein the durometer of the balloon
material is 90 A.
9. The catheter of claim 1, wherein the arteriotomy targeting aid
comprises a mechanical expansible device.
10. The catheter of claim 1, wherein the arteriotomy targeting aid
comprises an arteriotomy locating sensor.
11. The catheter of claim 10, wherein the arteriotomy locating
sensor comprises a temperature sensor.
12. The catheter of claim 11, wherein the temperature sensor is a
thermistor.
13. The catheter of claim 10, wherein the arteriotomy locating
sensor comprises a flow measurement sensor.
14. The catheter of claim 10, wherein the arteriotomy locating
sensor comprises an optical sensor.
15. The catheter of claim 10, wherein the arteriotomy locating
sensor comprises an impedance sensor.
16. The catheter of claim 10, wherein the arteriotomy locating
sensor comprises a Doppler sensor.
17. The catheter of claim 1, wherein the beacon comprises an
ultrasonic transmitter.
18. The catheter of claim 1, wherein the beacon comprises a radio
frequency transmitter.
19. The catheter of claim 1, wherein the beacon comprises a
magnetic field generator.
20. A method of determining the location of a therapeutic site in a
body, comprising: inserting a catheter into the body, wherein the
catheter comprises a targeting aid; and manipulating the catheter
such that the targeting aid is adjacent to or at the therapeutic
site.
21. The method of claim 20, wherein the therapeutic site is an
arteriotomy.
22. The method of claim 20, wherein manipulating the catheter
comprises moving the catheter until a Doppler signal from the
targeting aid determines that the targeting aid is adjacent to or
at the therapeutic site.
23. The method of claim 20, wherein the targeting aid comprises a
temperature sensor and manipulating the catheter comprises moving
the catheter until the temperature sensor indicates that it is
adjacent to or at the therapeutic site.
24. The method of claim 20, wherein the targeting aid comprises a
fluid flow detector and manipulating the catheter comprises moving
the catheter until the fluid flow detector indicates that it is
adjacent to or at the therapeutic site.
25. The method of claim 20, wherein the targeting aid comprises an
optical sensor and manipulating the catheter comprises moving the
catheter until the optical sensor indicates that it is adjacent to
or at the therapeutic site.
26. The method of claim 20, wherein the targeting aid comprises a
pressure sensor and manipulating the catheter comprises moving the
catheter until the pressure sensor indicates that it is adjacent to
or at the therapeutic site.
27. The method of claim 20, wherein the targeting aid comprises an
impedance sensor and manipulating the catheter comprises moving the
catheter until the impedance sensor indicates that it is adjacent
to or at the therapeutic site.
28. The method of claim 20, wherein the targeting aid comprises a
force detector and manipulating the catheter comprises moving the
catheter until the force detector indicates that it is adjacent to
or at the therapeutic site.
29. The method of claim 20, wherein the targeting aid comprises a
mechanically expansive device and the method comprises expanding
the mechanically expansive device and moving the catheter until the
device is adjacent to or at the therapeutic site.
30. The method of claim 20, wherein the targeting aid comprises an
inflatable balloon and the method comprises inflating the balloon
and moving the catheter until the balloon is adjacent to or at the
therapeutic site.
31. The method of claim 20, wherein: the therapeutic site is an
arteriotomy created by an introducer sheath inserted into an
artery; inserting the catheter into the body comprises inserting
the catheter and targeting aid through the lumen of the introducer
sheath past the arteriotomy and into the artery; and manipulating
the catheter comprises retracting the catheter such that the
targeting aid approaches the arteriotomy.
32. The method of claim 31, wherein the introducer sheath is
retracted simultaneously with retraction of the catheter.
33. The method of claim 31, wherein the targeting aid comprises an
inflatable balloon and wherein the balloon is inflated after
insertion of the catheter and prior to retracting the catheter.
34. The method of claim 31, further comprising applying compression
above the arteriotomy.
35. A method of determining the location of a therapeutic site in a
body relative to a therapeutic applicator, comprising: inserting a
targeting catheter into the body; identifying the location of the
therapeutic site using the targeting catheter; and determining the
position of the targeting catheter relative to the therapeutic
applicator.
36. The method of claim 35, wherein the therapeutic site is an
arteriotomy.
37. The method of claim 35, further comprising aligning the
therapeutic applicator with the therapeutic site based on the
relative position of the targeting catheter.
38. The method of claim 35, wherein determining the position of the
targeting catheter relative to the therapeutic applicator comprises
using triangulation.
39. The method of claim 38, wherein the triangulation is based on
magnetic fields.
40. The method of claim 38, wherein the triangulation is based on
acoustic signals.
41. The method of claim 40, wherein the triangulation is based on
an acoustic time-of-flight determination.
42. The method of claim 35, wherein determining the position of the
targeting catheter relative to the therapeutic applicator comprises
transmitting an ultrasound signal from a transmitter located on the
catheter to multiple receivers located on the therapeutic
applicator.
43. The method of claim 42, wherein the transmitter comprises a
piezoelectric cylinder.
44. The method of claim 42, wherein determining the position of the
targeting catheter relative to the therapeutic applicator comprises
determining the acoustic time-of-flight from the transmitter to the
receivers.
45. The method of claim 35, wherein determining the position of the
targeting catheter relative to the therapeutic applicator comprises
transmitting ultrasound signals from multiple transmitters located
on the therapeutic applicator to a receiver located on the
catheter.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional
Application No. 60/728,783, filed Oct. 20, 2005 and U.S.
Provisional Application No. 60/808,665, filed May 26, 2006, both of
which are incorporated herein by reference in their entirety.
BACKGROUND
[0002] 1. Field of the Invention
[0003] This disclosure relates to systems of methods for locating
arteriotomies. In some embodiments, the localization is used for
therapeutic targeting (e.g., for targeting of high-intensity
focused ultrasound).
[0004] 2. Description of the Related Art
[0005] Certain medical procedures result in bleeding penetration
wounds inside the body, for example via the insertion of devices
into blood vessels and/or organs. Representative procedures include
arterial and venous catheterization for cardiologic or radiologic
interventional procedures, needle biopsy procedures, and minimally
invasive surgery. Improved percutaneous catheterization techniques
have enabled physicians to perform an ever-increasing number of
diagnostic and therapeutic cardiovascular procedures using devices
deployed through arteries and veins. The annual number of
therapeutic and diagnostic catheterization procedures worldwide is
over 14 million and it is continuously growing.
[0006] In the vast majority of these catheterization procedures,
access to the vasculature is accomplished by percutaneous
installation of an introducer sheath into the common femoral
artery. The introducer sheath facilitates passage of a variety of
diagnostic and therapeutic instruments and devices into the vessel
and its tributaries. At the conclusion of the catheterization
procedure, the introducer sheath is removed, leaving an arteriotomy
that must be sealed. Arteriotomy hemostasis is most often
(approximately two-thirds of all cases) achieved by the application
of manual or mechanical compression (standard compression) on the
puncture site until a stable clot forms. Several important
limitations are associated with the use of standard compression.
For example, a physician, nurse, or trained technician must apply
digital pressure on the access site for up to 40 minutes. Patients
must remain on bed rest for three or more hours so as not to
disrupt clot formation in the arteriotomy. The most painful aspects
of the catheterization procedure reported by patients are the
standard compression procedure and lying immobile for hours. The
aggressive use of anticoagulants and antiplatelet therapies to
prevent thrombus formation during catheterization procedures has
greatly increased the difficulty of sealing the access site using
compression. Finally, complications occur, the most frequent of
which are the formation of hematomas, pseudo-aneurysms, and/or
arteriovenous fistulae.
[0007] Products for sealing arteriotomies based on newer
technologies such as collagen plugs, sealants and mechanical
suturing are being successfully marketed. However, these products
are invasive, implant foreign materials, require skill and training
to use, and can cause major complications. Accordingly, there is a
need for improved systems and methods for sealing arteriotomies
SUMMARY OF THE INVENTION
[0008] One embodiment described herein includes an arteriotomy
targeting catheter having an arteriotomy targeting aid coupled to
the catheter and adapted to detect the location of an arteriotomy
and one or more beacons coupled to the catheter proximal to the
arteriotomy targeting aid. In one embodiment, the arteriotomy
targeting aid comprises an inflatable balloon. In one embodiment,
the balloon comprises an elastic polymeric material. In one
embodiment, the soft elastic polymeric material is selected from
the group consisting of one or more of a polyamide, a polyamide
blend, a polyethylene, a polyethylene terephthalate, a
polyurethane, a polyamide, and a polyamide blend. In one
embodiment, the polyamide blend is PBAX. In one embodiment, the
durometer of the balloon material is between 20A and 90D. In one
embodiment, the durometer of the balloon material is between 80 A
and 65 D. In one embodiment, the durometer of the balloon material
is 90 A. In one embodiment, the arteriotomy targeting aid comprises
a mechanical expansible device. In one embodiment, the arteriotomy
targeting aid comprises an arteriotomy locating sensor. In one
embodiment, the arteriotomy locating sensor comprises a temperature
sensor. In one embodiment, the temperature sensor is a thermistor.
In one embodiment, the arteriotomy locating sensor comprises a flow
measurement sensor. In one embodiment, the arteriotomy locating
sensor comprises an optical sensor. In one embodiment, the
arteriotomy locating sensor comprises an impedance sensor. In one
embodiment, the arteriotomy locating sensor comprises a Doppler
sensor. In one embodiment, the beacon comprises an ultrasonic
transmitter. In one embodiment, the beacon comprises a radio
frequency transmitter. In one embodiment, the beacon comprises a
magnetic field generator.
[0009] Another embodiment described herein includes a method of
determining the location of a therapeutic site in a body,
comprising inserting a catheter into the body, wherein the catheter
comprises a targeting aid, and manipulating the catheter such that
the targeting aid is adjacent to or at the therapeutic site. In one
embodiment, the therapeutic site is an arteriotomy. In one
embodiment, manipulating the catheter comprises moving the catheter
until a Doppler signal from the targeting aid determines that the
targeting aid is adjacent to or at the therapeutic site. In one
embodiment, the targeting aid comprises a temperature sensor and
manipulating the catheter comprises moving the catheter until the
temperature sensor indicates that it is adjacent to or at the
therapeutic site. In one embodiment, the targeting aid comprises a
fluid flow detector and manipulating the catheter comprises moving
the catheter until the fluid flow detector indicates that it is
adjacent to or at the therapeutic site. In one embodiment, the
targeting aid comprises an optical sensor and manipulating the
catheter comprises moving the catheter until the optical sensor
indicates that it is adjacent to or at the therapeutic site. In one
embodiment, the targeting aid comprises a pressure sensor and
manipulating the catheter comprises moving the catheter until the
pressure sensor indicates that it is adjacent to or at the
therapeutic site. In one embodiment, the targeting aid comprises an
impedance sensor and manipulating the catheter comprises moving the
catheter until the impedance sensor indicates that it is adjacent
to or at the therapeutic site. In one embodiment, the targeting aid
comprises a force detector and manipulating the catheter comprises
moving the catheter until the force detector indicates that it is
adjacent to or at the therapeutic site. In one embodiment, the
targeting aid comprises a mechanically expansive device and the
method comprises expanding the mechanically expansive device and
moving the catheter until the device is adjacent to or at the
therapeutic site. In one embodiment, the targeting aid comprises an
inflatable balloon and the method comprises inflating the balloon
and moving the catheter until the balloon is adjacent to or at the
therapeutic site. In one embodiment, the therapeutic site is an
arteriotomy created by an introducer sheath inserted into an
artery, inserting the catheter into the body comprises inserting
the catheter and targeting aid through the lumen of the introducer
sheath past the arteriotomy and into the artery, and manipulating
the catheter comprises retracting the catheter such that the
targeting aid approaches the arteriotomy. In one embodiment, the
introducer sheath is retracted simultaneously with retraction of
the catheter. In one embodiment, the targeting aid comprises an
inflatable balloon and wherein the balloon is inflated after
insertion of the catheter and prior to retracting the catheter. One
embodiment further includes applying compression above the
arteriotomy.
[0010] Another embodiment described herein includes a method of
determining the location of a therapeutic site in a body relative
to a therapeutic applicator, comprising inserting a targeting
catheter into the body, identifying the location of the therapeutic
site using the targeting catheter, and determining the position of
the targeting catheter relative to the therapeutic applicator. In
one embodiment, the therapeutic site is an arteriotomy. One
embodiment further comprises aligning the therapeutic applicator
with the therapeutic site based on the relative position of the
targeting catheter. In one embodiment, determining the position of
the targeting catheter relative to the therapeutic applicator
comprises using triangulation. In one embodiment, the triangulation
is based on magnetic fields. In one embodiment, the triangulation
is based on acoustic signals. In one embodiment, the triangulation
is based on an acoustic time-of-flight determination. In one
embodiment, determining the position of the targeting catheter
relative to the therapeutic applicator comprises transmitting an
ultrasound signal from a transmitter located on the catheter to
multiple receivers located on the therapeutic applicator. In one
embodiment, the transmitter comprises a piezoelectric cylinder. In
one embodiment, determining the position of the targeting catheter
relative to the therapeutic applicator comprises determining the
acoustic time-of-flight from the transmitter to the receivers. In
one embodiment, determining the position of the targeting catheter
relative to the therapeutic applicator comprises transmitting
ultrasound signals from multiple transmitters located on the
therapeutic applicator to a receiver located on the catheter.
[0011] Another embodiment described herein includes a method for
sealing a vascular opening in a blood vessel, comprising
transiently substantially occluding the blood vessel, applying
energy adjacent to the vascular opening such that the opening is
sealed, and removing the blood vessel occlusion. In one embodiment,
the blood vessel is a fermoral, brachial, or radial artery. In one
embodiment, the blood vessel is transiently fully occluded. In one
embodiment, occluding the blood vessel comprises applying
compressive force to the blood vessel. In one embodiment, the
compressive force is applied using an energy applicator that is
used to apply the energy. In one embodiment, the compressive force
is applied to the surface of skin located over the blood vessel. In
one embodiment, applying energy adjacent to the vascular opening
comprises directing energy from an energy applicator located on or
near the surface of skin over the blood vessel. In one embodiment,
applying energy to the vascular opening comprises energizing an
energy applicator positioned inside a patient near the vascular
opening. In one embodiment, the energy applied is acoustic energy.
In one embodiment, the energy applied is high intensity focused
ultrasound energy. In one embodiment, the energy applied is radio
frequency energy. In one embodiment, the energy applied is
microwave energy. In one embodiment, the energy applied is optical
energy. In one embodiment, the optical energy comprises one or more
of ultraviolet, visible, near-infrared, or infrared energy. In one
embodiment, the energy is thermal energy. In one embodiment, the
energy is cryogenic energy.
[0012] Another embodiment described herein includes a method for
sealing a vascular opening in a blood vessel in a patient,
comprising inserting a targeting catheter into the blood vessel,
locating the vascular opening using the targeting catheter,
aligning a therapeutic energy applicator relative to the targeting
catheter, initiating a station keeping algorithm configured to
detect relative motion between tissue in the vicinity of the
vascular opening and the applicator, and applying energy from the
applicator to tissue adjacent to the vascular opening to seal the
opening. In one embodiment, inserting the targeting catheter
comprises inserting the catheter through the vascular opening. In
one embodiment, the vascular opening is created by insertion of an
introducer sheath and inserting the targeting catheter comprises
inserting the catheter through the sheath. In one embodiment,
locating the vascular opening comprises manipulating the targeting
catheter until a targeting aid on the catheter is adjacent to or at
the vascular opening. In one embodiment, aligning the therapeutic
energy applicator comprises detecting the position of the
applicator relative to a beacon located on the catheter. In one
embodiment, detecting the position of the applicator relative to
the beacon comprises emitting an ultrasonic signal from the beacon
to multiple receivers on the applicator. In one embodiment, the
energy is high intensity focused ultrasound. One embodiment
includes withdrawing the catheter from the blood vessel prior to
applying energy from the applicator. In one embodiment, the
targeting catheter remains in the patient's body during application
of the energy. In one embodiment, the targeting catheter is removed
from the patient's body prior to application of the energy. One
embodiment includes applying pressure to the blood vessel to
transiently partially or fully occlude the vessel prior to
initiating station keeping.
[0013] Another embodiment described herein includes a method of
detecting tissue movement relative to an ultrasound applicator,
comprising emitting first ultrasonic pulses from at least three
ultrasound transducers to a target point in the tissue, detecting
first ultrasonic echoes with the ultrasound transducers, emitting
second ultrasonic pulses from the ultrasound transducers, detecting
second ultrasonic echoes with the ultrasound transducers, comparing
the first and second ultrasonic echoes, and determining the amount
of relative tissue movement using the comparison and directional
vectors between the ultrasound transducers and the target point. In
one embodiment, comparing the first and second ultrasonic echoes
comprises determining time shifts between the echoes. In one
embodiment, comparing the first and second ultrasonic echoes
comprises determining phase differences between the echoes. In one
embodiment, determining the amount of relative tissue movement
comprises executing a recursive algorithm. In one embodiment,
experimentally determining the directional vectors.
[0014] Another embodiment described herein includes a method of
detecting tissue movement relative to an ultrasound applicator,
comprising emitting a first ultrasonic pulse from a first
ultrasound transducer to a target point in the tissue, detecting a
first ultrasonic echo at a second and third ultrasound transducer,
emitting a second ultrasonic pulse from either the second or third
ultrasound transducer to the target point, detecting a second
ultrasonic echo at the first ultrasound transducer and the
non-transmitting second or third ultrasound transducer, comparing
the echoes to previously recorded echoes, and determining the
amount of relative tissue movement using the comparison and
directional vectors between the ultrasound transducers and the
target point. One embodiment includes detecting the first and
second ultrasonic echoes at at least one additional ultrasound
transducer. In one embodiment, comparing the echoes comprises
determining time shifts between the detected echoes and the
previously recorded echoes. In one embodiment, comparing the echoes
comprises determining phase differences between the detected echoes
and the previously recorded echoes. In one embodiment, determining
the amount of relative tissue movement comprises executing a
recursive algorithm. One embodiment includes experimentally
determining the directional vectors.
[0015] Another embodiment described herein includes a method of
detecting tissue movement relative to an ultrasound applicator,
comprising emitting an ultrasonic pulse from a first ultrasound
transducer to a target point in the tissue, detecting an ultrasonic
echo at the first ultrasound transducer and at a second and third
ultrasound transducer, comparing the echo to a previously recorded
echo, and determining the amount of relative tissue movement using
the comparison and directional vectors between the ultrasound
transducers and the target point. One embodiment comprises
detecting the ultrasonic echo at at least one additional ultrasound
transducer. In one embodiment, comparing the echo comprises
determining time shifts between the detected echo and the
previously recorded echo. In one embodiment, comparing the echo
comprises determining phase differences between the detected echo
and the previously recorded echo. In one embodiment, determining
the amount of relative tissue movement comprises executing a
recursive algorithm. On embodiment includes experimentally
determining the directional vectors.
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] FIG. 1 depicts an ultrasound applicator and a visualization
of the focused, high intensity ultrasound emitted from the
applicator.
[0017] FIGS. 2A-2C are micrographs of femoral arteriotomies sealed
with focused ultrasound. FIG. 2A illustrates a sealed ovine femoral
artery. FIG. 2B illustrates a sealed swine femoral artery. FIG. 2C
illustrates the same artery as FIG. 2B, but viewing it from the
intimal surface.
[0018] FIG. 3 is a perspective view of an acoustic hemostasis
system.
[0019] FIG. 4A depicts a hand-held therapeutic applicator being
positioned onto a patient.
[0020] FIG. 4B is an illustration of the user interface screen
located on the hand-held therapeutic applicator.
[0021] FIG. 5 is a flowchart depicting one embodiment of an overall
system vascular closure procedure.
[0022] FIG. 6 is a diagram of an introducer sheath located in an
femoral artery.
[0023] FIG. 7A is a diagram of a vascular closure procedure
illustrating the insertion of a targeting catheter into a vessel
through an introducer sheath.
[0024] FIG. 7B is a diagram of a vascular closure procedure
illustrating the inflation of a targeting balloon and compression
from a therapeutic applicator.
[0025] FIG. 7C is a diagram of a vascular closure procedure
illustrating arteriotomy localization.
[0026] FIG. 7D is a diagram of a vascular closure procedure
illustrating alignment of a therapeutic applicator to the
arteriotomy.
[0027] FIG. 7E is a diagram of a vascular closure procedure
illustrating compression applied to either partially occlude or
fully occlude the artery prior to focused energy treatment.
[0028] FIG. 7F is a diagram of a vascular closure procedure at the
initiation of station keeping.
[0029] FIG. 7G is a diagram of the vascular closure procedure
illustrating the withdrawal of the targeting catheter from the
artery.
[0030] FIG. 7H is a diagram of the vascular closure procedure
illustrating the dosing of the focused ultrasound in order to
perform acoustic arterial hemostasis.
[0031] FIG. 8 is a perspective view of a balloon targeting
catheter.
[0032] FIG. 9 is a diagram of the balloon targeting catheter and
associated components.
[0033] FIG. 10A is a longitudinal cross-sectional view of the
distal section of a balloon targeting catheter.
[0034] FIG. 10B is an axial cross-sectional view of the distal
section of a balloon targeting catheter.
[0035] FIG. 10C an end view of the distal section of a balloon
targeting catheter.
[0036] FIG, 10D is a longitudinal cross-sectional view of the
distal section of a balloon targeting catheter.
[0037] FIG. 11 is a diagram illustrating the targeting catheter and
ultrasound applicator after arterial localization with the
arteriotomy locating beacon emitting ultrasound waves.
[0038] FIG. 12 is an illustration of the user interface for
targeting on the arteriotomy.
[0039] FIG. 13 is a schematic illustrating acoustic time of flight
targeting of the therapeutic applicator.
[0040] FIG. 14 is a schematic of a cylindrical piezoelectric
arteriotomy locating beacon having three possible modes of
operation.
[0041] FIG. 15 is a schematic of a therapeutic applicator face
having CW/PW Doppler mode transducers, ATOF receivers, and
therapeutic transducers.
[0042] FIG. 16 is a graph showing voltage measured on a
piezoelectric element from external stress (hard surface).
[0043] FIG. 17 is a graph showing voltage measured on a
piezoelectric element from external stress (thumb).
[0044] FIG. 18 is a graph showing the accuracy of station keeping
detected movement in the X-axis using a pitch-catch algorithm.
[0045] FIG. 19 is a graph showing the accuracy of station keeping
detected movement in the Y-axis using a pitch-catch algorithm.
[0046] FIG. 20 is a graph showing the accuracy of station keeping
detected movement in the Z-axis using a pitch-catch algorithm.
[0047] FIG. 21 depicts three graphs showing station keeping
detected motion tional approach for elevation rotation.
[0048] FIG. 22 depicts three graphs showing station keeping
detected motion tional approach for roll rotation.
[0049] FIG. 23 depicts three graphs showing station keeping
detected motion e approach for elevation rotation.
[0050] FIG. 24 depicts three graphs showing station keeping
detected motion e approach for roll rotation.
[0051] FIG. 25 depicts three graphs showing the accuracy of station
keeping ent using a calculated direction matrix along the X-axis,
Y-axis, and Z-axis,
[0052] FIG. 26 depicts three graphs showing the accuracy of station
keeping detected movement using a measured direction matrix along
the X-axis, Y-axis, and Z-axis, respectively.
[0053] FIG. 27 is a block diagram showing a station keeping
system.
[0054] FIG. 28 is a schematic depicting a transucer concept that
uses three phased arrays to multiple points along the z-axis.
[0055] FIG. 29 is a flow chart depicting a Radio Frequency
Ultrasound Motion Estimate algorithm for station keeping.
[0056] FIG. 30 is an illustration of an ultrasound appliactor user
interface during therapeutic dosing.
[0057] FIG. 31 is an illustration of a targeting catheter having a
piezoelectric Doppler device as a targeting aid.
[0058] FIG. 32 is a schematic of a targeting catheter located in a
femoral artery.
[0059] FIGS. 33A-33C are illustrations of a user interface on the
therapeutic applicator.
[0060] FIG. 34 is a schematic illustrating the determination of the
distance between an arteriotomy and a beacon/arteriotomy
sensor.
[0061] FIG. 35 is a block diagram of an arteriotomy locating
system.
[0062] FIG. 36 is a schematic of a forward looking Doppler
arteriotomy locating sensor.
[0063] FIG. 37 is a schematic of a side looking Doppler arteriotomy
locating sensor.
[0064] FIG. 38 is a schematic of a Z-matching arteriotomy locating
sensor.
[0065] FIG. 39 is a schematic of a TDTM probe having a single
thermistor at its tip.
[0066] FIG. 40 is a graph of temperature signals from a thermistor
bead on a TDTM probe.
[0067] FIG. 41 is a graph of temperature signals from a thermistor
bead on a TDTM probe while bleeding is simulated using dropwise
flow pulses.
[0068] FIG. 42 is a schematic of a TDTM probe having a single
thermistor at its tip under pulsatile flood flow.
[0069] FIG. 43A is a graph of temperature differential measured
from experimental setup of FIG. 42 while the TDTM probe bead is
moved from the lumen of the femoral artery into the puncture
track.
[0070] FIG. 43B is a graph of temperature differential measured
from experimental setup of FIG. 42 while the TDTM probe bead is
moved from the puncture track under maximal compression (no track
bleeding) conditions directly to the lumen of the femoral
artery.
[0071] FIG. 44 is a schematic of a TDTM probe having dual
thermistor beads near its tip under in vivo pulsatile blood flow
conditions.
[0072] FIG. 45 is a graph of temperature signals from the TDTM
probe of FIG. 44. The TDTM probe is moved from the positions of
both beads located in the lumen to both beads in the puncture
track.
[0073] FIG. 46 is a schematic of a TDTM probe having three
thermistor beads near its tip.
[0074] FIG. 47 is a graph of temperature differentials measured
from a TDTM probe with dual beads in response to therapeutic energy
test power pulses delivered from a focused ultrasound
applicator.
[0075] FIG. 48 is a schematic of a TDTM probe having two
thermistors in conjunction with a non-thermistor partner
sensor.
[0076] FIG. 49 is a schematic of a TDTM probe used in conjunction
with an invasive cautery or puncture sealing device.
[0077] FIG. 50 is a schematic of an experimental setup for
measuring the effects of transient arterial occlusion.
[0078] FIG. 51 is a photograph of the setup depicted in FIG.
50.
[0079] FIG. 52 is a graph of temperature change during heating of
the experimental setup of FIG. 50 and 51.
[0080] FIG. 53 is a photograph of the cross-section of the artery
treated in the experiment of FIG. 50-52.
DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS
[0081] Disclosed herein are systems and methods associated with an
acoustic hemostasis device. This device, designed for rapid,
noninvasive sealing of femoral arteriotomies using focused
ultrasound technology, requires neither the prolonged application
of pressure and immobilization associated with standard
compression, nor implantation of any foreign material. Thus, this
system has the potential to provide a superior method of
arteriotomy closure. This system has been also described in U.S.
Pat. No. 6,656,136, filed Oct. 25, 2000; co-pending U.S.
application Ser. No. 10/671,417 filed Sep. 24, 2003; U.S. Pat. No.
6,719,694, filed Dec. 22, 2000; and U.S. Pat. No. 6,626,855, filed
Nov. 22, 2000; all of which are incorporated herein by reference in
their entirety.
[0082] Because of its unique properties in soft tissue, medical
ultrasound can be brought to a tight focus at a distance from its
source. FIG. 1 depicts an ultrasound applicator 20 emitting focused
ultrasound to a focal volume 5. The ultrasound energy is modeled
using the Schlieren technique. FIG. 1 illustrates the ability to
tightly focus ultrasound waves in soft tissue at a distance from
its source. If sufficient energy is radiated from an ultrasound
source (e.g. ultrasound applicator 20), tissue located in the focal
volume 5 can be rapidly heated while intervening and adjacent
tissues are unaffected. By precisely controlling the magnitude,
location and distribution of the focused ultrasound, noninvasive
therapies such as arterial puncture sealing can be rapidly and
safely administered.
[0083] Animal and human studies have show that use of
high-intensity focused ultrasound to locally heat punctures and
lacerations in arterial and venous walls can affect rapid and
durable sealing (acoustic hemostasis) of these wounds.
[0084] The acoustic hemostasis sealing mechanism relies not on
blood coagulation, but rather on the formation of a thermally
coagulated collagen cap that adheres to the external elastic lamina
and thereby seals the arteriotomy. This method of arteriotomy
closure is noninvasive, acts on collagen naturally present in the
adventitial and perivascular tissues, is unaffected by
periprocedural anticoagulation therapy, is effective over a
spectrum of wound and vessel sizes, and occurs in a matter of
seconds.
[0085] In some embodiments, successful acoustic hemostasis
treatment is promoted by: (1) adequate compression of the
arteriotomy to obviate bleeding, and the consequential convective
heat loss, during energy delivery, and to approximate the edges of
the arteriotomy; (2) accurate spatial targeting of the ultrasound
energy on the arteriotomy site; and (3) sufficient ultrasound
energy to coagulate (denature) native collagen in the adventitial
and perivascular tissues. In some embodiments, the ultrasonic
systems described herein are designed to satisfy each of these
requirements over a diverse patient population and to do so while
accommodating the varying skill levels of users.
[0086] In some embodiments, the ultrasonic system is intended for
noninvasively sealing femoral arteriotomies and reducing time to
hemostasis, ambulation and eligibility for hospital discharge in
subjects who have undergone diagnostic or interventional
catheterization procedures using an 8 French or smaller introducer
sheath. However, the system may also be used for other purposes,
with other subjects, and other catheterization procedures.
[0087] In some embodiments, the system and methods described herein
may be used with other energy sources besides ultrasound sources.
For example, in some embodiments, a radio frequency, microwave,
optical, or thermal therapeutic applicator may be used. In some
embodiments, the optical applicator may provide one or more of
ultraviolet, visible, near-infrared, or infrared energy. In various
embodiments, the thermal applicator may provide heating or
cryogenic energy.
[0088] Histopathological examinations of extirpated ovine and
porcine arteries treated with varying doses (i.e., intensity and
duration of exposure) of focused ultrasound that exceeded the
threshold dose for arteriotomy sealing were performed to elucidate
the healing pathway subsequent to acoustic hemostasis. Generally,
within 14 days post catheterization using a 5F introducer sheath,
the blood clots that form in the arteriotomy, adventitia and
perivascular tissue were infiltrated with spindle-shaped
transformed smooth muscle cells that produced collagen matrix.
There was minimal to mild neointimal proliferation lining the lumen
of the artery in the areas of trauma from the catheter puncture,
and the neointima was covered by intact endothelium with no
evidence of mural thrombus formation in the treated areas.
[0089] The arteries examined 30 days following the acoustic
hemostasis procedure were completely healed. The neointima was well
organized, covered by intact endothelium, and increased only a
minimal amount from the thickness at 14 days post treatment.
Neovascularization of the healed tissue and neointima was more
prominent than at 14 days and appeared to be stabile by 60 days
post treatment.
[0090] At 60 days following catheterization, the arteries were
completely healed and quiescent. The neointima was stabile, covered
with endothelium and no longer proliferating. There was no
morphological evidence of vessel wall weakness resulting from the
focused ultrasound exposure.
[0091] FIGS. 2A-2C illustrate microscope photographs of femoral
arteriotomies sealed with focused ultrasound and then extirpated
within 30 minutes of treatment. FIG. 2A is a cross-sectional
photograph of an ovine femoral artery. The arteriotomy is sealed by
formation of a coagulated collagen cap 10 on the external elastic
lamina 12. An acute fibrin clot 14 with trapped coagulated red
blood cells forms under the collagen cap and extendes partially
into the vessel lumen 16. The intrinsic fibrinolytic system
prevents these clots from expanding into the lumen and occluding it
with an acute thrombus. FIG. 2B is a photograph of a swine femoral
artery illustrating that ultrasound-induced coagulaum 18 completely
covers the arteriotomy site (adventititial surface of artery)
forming a robust membrane that seals the wound. FIG. 2C illustrates
the same arteriotomy as FIG. 2B, but viewing it from the intimal
surface. (The fibrin clot has been extracted to facilitate
visualization of thermally coagulated native collagen.) Note that
the coagulum typically fills about 20% of the thickness of the
arterial wall from the adventitial surface.
[0092] In some embodiments the ultrasonic systems described herein
may be a compact, mobile, self-contained, therapeutic ultrasound
system. In some embodiments the ultrasonic system comprises four
major components: applicator, generator, targeting catheter, and
disposable patient interface (DPI). FIG. 3 illustrates one such
compact system having a generator 24 on a movable cart that is
connected to a hand-held ultrasound applicator 20.
[0093] The applicator may be a handheld device that comprises an
ergonomic plastic housing, a display with graphical user interface,
and a multiplicity of transducers that facilitate treatment
targeting, maintenance of proper arteriotomy compression during
treatment, and delivery of focused ultrasound sufficient to seal
the arteriotomy. As illustrated in FIG. 4A, the hand-held
applicator 20 may be conveniently handled by a physician during the
procedure for applying compression and properly positioning the
ultrasound transducers relative to the arteriotomy. The applicator
20 may include a display 25 such as depicted in FIG. 4B to provide
compression and/pr targeting feedback to the user. Although in one
embodiment, the applicator provides therapeutic ultrasound, other
therapeutic applications may be used (e.g., providing laser, rf,
microwave, or heat energy for therapeutic use).
[0094] The generator may include a power supply; a central
processing unit and operating system; and the hardware and software
modules that enable the user interface, targeting,
compression-monitoring, dosimetry,
focused-ultrasound-energy-delivery and station-keeping functions.
The generator may also provide a means to transport and maneuver
the system, and to store the applicator when not in use.
[0095] The targeting catheter may include any catheter having one
or more targeting aids for locating and targeting the arteriotomy.
The targeting catheter may be placed down the lumen of the
procedure introducer sheath or inserted in any other fashion into
an artery containing an arteriotomy. In various embodiments, the
targeting aid may include an inflatable balloon, force detectors,
optical sensors, pressure sensors, impedance sensors, mechanically
expansive devices, temperature sensors (e.g., thermisters), and/or
Doppler sensors. In one embodiment, the targeting catheter features
an arteriotomy locator beacon (e.g., a small ultrasound transducer)
in addition to the targeting aid(s). The beacon may be used to
determine the location of the beacon and/or targeting aids in
reference to the therapeutic applicator. In one embodiment, the
beacon is located in the catheter shaft and slightly proximal to a
balloon and transmits ultrasonic pulses that serve to signal its
position relative to the applicator.
[0096] The disposable patient interface, DPI, is a sterile,
single-use, polymeric device that envelops the applicator and is
designed to maintain the sterile field and serves as an acoustic
coupling medium between the applicator and the patient's skin. Some
examples of a suitable DPI are described in more detail in U.S.
Application Publication No. 2005-0215901, filed Jan. 18, 2006,
which is incorporated herein by reference in its entirety.
[0097] FIG. 5 is a flow chart illustrating the procedural steps for
one method of performing acoustic arterial hemostasis. It will be
appreciated that, depending on the embodiment, some steps may be
removed or added or may be conducted in an order different from
that indicted above. Each step is described in more detail below.
It will also be appreciated that these steps may be used for any
treatment involving focusing energy to a treatment site and not
just for closing an arteriotomy.
[0098] At block 100 in FIG. 5, a targeting catheter is inserted to
aid in the localization of an arteriotomy or other site where
treatment is desired. In embodiments where a femoral arteriotomy is
to be treated, the acoustic targeting catheter may be placed into
the femoral artery through an introducer sheath prior to ultrasonic
treatment. In one embodiment, this targeting catheter comprises a
guidewire like device having one or more features that enable the
catheter to locate an arteriotomy (e.g. using an inflatable
balloon, force detectors, optical sensors, pressure sensors,
impedance sensors, mechanically expansive devices, temperature
sensors, and/or Doppler sensors), report the position of the
arteriotomy relative to the therapy delivery device (e.g., using
beacon such as an ultrasonic beacon), and/or measure blood flow
properties (e.g., using sensors to measure blood velocity,
volumetric flow rates, pressure, etc.).
[0099] FIG. 6 is a schematic illustrating a percutaneous
catheterization procedure which involves insertion of an introducer
sheath 26 into the fermoral artery 28. When the sheath is removed,
the resulting arteriotomy 30 must be sealed to prevent hemorrhage.
FIG. 7A is a schematic illustrating the insertion of a targeting
catheter 32 through the introducer sheath 26 located in the femoral
artery 28. Also depicted in the schematic is the intervening tissue
30 through which the sheath 26 extends. The targeting catheter 32
includes a targeting aid 34 (e.g., an inflatable balloon), a beacon
36, and a soft flexible tip 37 at the end of the targeting catheter
32. However, is should be noted that targeting catheters containing
other features described herein may be used.
[0100] In one embodiment, the targeting catheter 32 includes a
sterile, single-use, balloon catheter that is placed down the lumen
of the procedure introducer sheath. FIG. 8 depicts a targeting
catheter 32 having an inflatable balloon 34 (shown inflated) as a
targeting aid and a beacon 36 (e.g., an ultrasound transducer
located within the catheter shaft and slightly proximal to the
balloon). As described in more detail below, the balloon 34 may be
used to locate the arteriotomy. The beacon 36 may then be used to
signal its position relative to the applicator, for example, by
transmitting ultrasonic pulses.
[0101] In some embodiments, the catheter outside diameter is less
than 4 French (1.33 mm). Thus, in some such embodiments, the beacon
36 is a micro-beacon with an outside diameter is less than 1.33 mm.
In various embodiments, the beacon 36 may pass position information
from inside human body to an external system using either an
electromagnetic method or a mechanical (e.g. acoustic) method.
Provided below is a description of an ultrasound beacon and an
electromagnetic beacon suitable for use as described herein.
[0102] An ultrasound beacon 36 may be made from piezo-ceramic
material (e.g., one or more ultrasonic transducers). The ultrasound
beacon 36 can either work in transmitter mode, in which the beacon
36 transmits an ultrasound wave when an RF electrical source is
applied on its surface, or receiving mode, in which the beacon 36
generates an electrical RF signal when a mechanical wave hits its
surface. An acoustic time of flight (ATOF) system may used to
detect the beacon 36 position inside a human body (as described in
more detail below with respect to block 204 of FIG. 5).
[0103] In one embodiment, the beacon 36 in the ATOF system can be a
piezo-ceramic tube, which may have an outside diameter of about 1
mm and produces an ultrasound wave around 1.3 MHz when using a hoop
vibration mode. The beacon's 36 position on the catheter may be
designed to be at a known and repeatable spatial relationship
relative to the targeting aid 34 (e.g., a specified distance from
the edge of a targeting balloon, which can be positioned to touch
the arteriotomy when inflated inside the artery).
[0104] Although an ultrasonic beacon system has been described, it
will be appreciated that any beacon system that can be fit into the
desired biological system (e.g., artery) may be used to detect the
position of the beacon, and consequently, the position of the
targeting aid (e.g., balloon). For example, an electromagnetic
sensor, such as microbars (available from Ascension Technology
Corporation, Burlington, vt.), and a 3D space tracking system may
achieve the same result as an ultrasonic beacon used in conjunction
with ATOF methods.
[0105] FIG. 9 is a schematic depicting an overview of the
components that may be directly associated with a balloon targeting
catheter as described above. The catheter 32, balloon 34, floppy
distal tip 37 and beacon 36 may be attached by way of a flexible
body tube to a hub 42 that provides for interconnections to
electrical drive and inflate/deflate functions.
[0106] The beacon 36 may be electrically coupled to a cable 44,
which may be strain relief mounted into the hub 42. There is
optionally an electrical matching component or network 46 inside
the hub that transforms an impedance to improve electrical
efficiency of the system and/or pulse shape transmitted by the
beacon. Additionally there may be an electrical connector 60 on the
terminus end of the cable.
[0107] Syringes 48 and 50 and their associated valves 52 and 54 may
be used for fluid (e.g., sterile saline) injection and removal
(e.g., to prime the balloon prior to use and to inflate and deflate
the balloon after it has been inserted into the artery).
Alternatively, a multi-port device designed for one-handed
operation may be used. For example, fluid management devices that
are spring loaded may be used, permitting release of the balloon
fill by pushing one button.
[0108] The system may also include pressure gauge 56 to monitor or
control the pressure or volume in the balloon. Those of skill in
the art will recognize that pressure gauge 56 may be representative
of any component (or various components) that achieves the effect
of monitoring or controlling the pressure or volume in the balloon.
It may also be advantageous to provide for a pressure regulation or
release when the artery is fully compressed. This ability protects
both the arterial wall and the balloon from compressive damage and
can facilitate a more accurate location of the beacon 36 at the
arteriotomy site throughout the compression sequence.
[0109] An insertion tool 58 may be provided to facilitate insertion
of the distal tip 37 of the catheter 32 into an introducer sheath
already inserted into a patient's artery. The insertion tool 58 may
have a tapered distal tip suitable to be inserted into and to open
the hemostatic valve on the introducer sheath (see FIG. 6) and has
a constriction in its internal bore proximal to the location of the
balloon that restricts bleeding through the device. This
restriction may be designed to have a close fit to the diameter of
the catheter body but still allow for free movement. In one
embodiment, a close fit may be provided using a soft elastomeric
material, thus providing a sealing function.
[0110] FIG. 10A, 10B, 10C, and 10D illustrate the design and
construction of the distal section of one embodiment of a balloon
targeting catheter in more detail. Referring to FIG. 10A, the
catheter is substantially a coaxial design. Balloon 34 may be any
suitable pliable material. In one embodiment, balloon 34 is made of
soft, elastic polyurethane of a Durometer between 80A and 65D. The
balloon 34 may be nominally between 3 and 7 mm in diameter. In some
embodiments, the shape of the balloon 34 is not optimally spherical
but rather a modified sphere foreshortened in its axial dimension
in order to provide a large "footprint" against the artery wall but
not to fully occlude blood flow in the artery. These shape
variations may be accomplished using one of two methods, which may
be used singly or in combination with one another. In one
embodiment, the balloon may be foreshortened by locating the distal
attach point 62 closer to the proximal attach point, thus
"pooching" in the balloon. This "pooching" creates a non-spherical
distal end for the balloon. Additionally, the neck of the balloon
may be mounted to the core tube 64 in an inverted manner wherein
the mounting point is effectively inside the balloon. The
advantages of this inverted mounting technique include: i) allowing
for a larger "footprint" against the artery wall and ii) mounting
the balloon ends effectively inside the balloon allows the
piezoelectric beacon to not have a layer of bonded balloon material
located between it and the patient, thereby allowing for improved
acoustic transmission properties.
[0111] Alternatively, the balloon 34 may be fabricated from stiff,
essentially inelastic materials such as polyester or PET. These
balloons hold an inflated shape more consistently than the
polyurethane balloons and require/tolerate much higher inflation
pressures. In some embodiments, unfold and refold characteristics
may be tailored such that upon deployment, a smooth contact with
the elements of the vessel is presented.
[0112] In some embodiments, the catheter may include a core tube
64. The core tube 64 may provide structural stiffness
longitudinally, assuring integrity of the catheter assembly. In
addition, the core tube 64 provides one or more internal lumens in
which fluid can be transported to/from the balloon, and, with a
diameter less than the overall body 66 diameter, provides a place
where the deflated balloon may nest during insertion and removal.
As depicted in the cross-sectional view of FIG. 10B, the core tube
64 may include two lumens (e.g., in a "double-D" configuration).
One lumen may be used for fill and the other for venting, thus
facilitating quick priming and removal of air bubbles. (Note that
the holes in the core tube inside the balloon are not shown on of
FIG. 10A through 10D.) The core tube is advantageously made of a
higher Durometer (e.g. 55D to 75D) polyurethane that is compatible
with being thermally bonded to other components in the catheter,
most importantly the balloon 34.
[0113] Further describing the design, core tube 66 passes through
the inside diameter of cylindrical beacon 36 and is terminated and
interconnected at the hub 42 (see FIG. 9). It is advantageous to
provide an enhanced flexibility of the catheter at that point
immediately distal to the location of the beacon (and immediately
proximal to the balloon) as depicted as section 68 on FIG. 10A.
This location is also that of the thermal bond mounting the balloon
to core tube 64. This flexibility permits the balloon to more
flatly locate to and seal the arteriotomy even as the catheter is
being pulled up at the angle of the entry channel (or track).
[0114] Proximal to the beacon 36, the core tube 66 may be
positioned within a body tube 70, which may have an about 1 mm
outside diameter and be made from polyurethane. Use of polyurethane
promotes thermal bonding and melding with a jacket that covers
beacon 36.
[0115] FIG. 10B is a rendering of the distal cross-section of a
balloon targeting catheter from a view proximal to the beacon
location. This view also depicts the location of wires extending
through the catheter to the beacon 36. FIG. 10C depicts an end view
of the distal end of the balloon targeting catheter showing the
core tube 64 in cross-section. FIG. 10D depicts a cross-sectional
view longitudinally through the distal portion of the balloon
targeting catheter.
[0116] Returning to the discussion of the flow chart in FIG. 5, at
block 102, after insertion of the targeting catheter, the balloon
34 is inflated once its position is known to be past the
arteriotomy 30. FIG. 7B depicts the inflation of the balloon 34
within the artery 28 beyond the distal opening of the introducer
sheath 30. The balloon 34 may be inflated with any suitable fluid
such as a liquid (e.g. a sterile saline solution). The user next
(or simultaneously) applies compression with the applicator 20 to
stop blood flow in the tract 33 through the tissue 31 that is
formed by the introducer sheath 26.
[0117] At block 104 in FIG. 5, the introducer sheath 26 and
targeting catheter 32 are retracted from the artery 28 as a unit
until the balloon 34 comes into contact with the vessel wall at the
arteriotomy site 30 (FIG. 7C). In this position, egress of blood
from the artery through the tract 33 is impeded by the balloon 34
and the arteriotomy locator beacon is situated within the
arteriotomy. Thus, by retracting the balloon until it contacts the
artery 28 wall, the arteriotomy site 30 is localized.
[0118] Next, at block 106 of FIG. 5, the pressure applied to the
applicator 20 may be released so as to allow for easier alignment
of the applicator 20 relative to the arteriotomy 30 as illustrated
in FIG. 7D. The targeting aid balloon 34 will serve to stop blood
flow up the track 33 during this process. A cluster of receivers in
the applicator may be used to detect ultrasonic pulses transmitted
from the arteriotomy locator beacon 36 and targeting algorithms
resident in the generator may continuously analyze these signals
and produce graphical feedback on the applicator 20 display (e.g.,
utilizing acoustic time of flight (ATOF) algorithms). Using this
intuitive information, the user is enabled to quickly and
accurately target the focused ultrasound at the arteriotomy site
30.
[0119] As noted, acoustic Time-of-Flight (ATOF) may be utilized to
determine the position of the beacon 36 relative to the therapeutic
applicator 20. In some alternative embodiments, a separate beacon
is not included on the targeting catheter (for example, where the
arteriotomy targeting aid is capable of ultrasound generation, such
as when it is a Doppler beacon or a resistance heated PZT). In such
embodiments, the targeting aid in effect also serves as the
acoustic beacon. Accordingly, the ATOF methods described herein can
also be used in these alternative embodiments.
[0120] The PZT element (either in beacon 36 or as part of the
targeting aid 34) may be utilized as a highly localized sound
source marker, easily visible in an ultrasound image or detected
and localized in an Acoustic Time of Flight detection system. In
one ATOF approach, the beacon transmits tone bursts of sound to
receivers encircling the outer perimeter of the therapeutic
applicator. The in-situ beacon is pulsed while each of the
receivers independently measures the time for the pulse to arrive.
When the time of flight to each receiver is known and the time has
been converted to a distance between the beacon and the receiver,
then the position of the beacon relative to the receivers can be
calculated using triangulation. A minimum of three receivers may be
used to calculate the X, Y and Z position of the beacon relative to
the Therapeutic Applicator. If more than three sensors are used,
the accuracy of the position calculation can be improved.
[0121] By continuously monitoring the position of the arteriotomy
relative to the therapeutic applicator via ATOF, the user can
adjust the position and orientation of the applicator such that the
therapeutic energy source focus (e.g., laser, RF, ultrasound, or
microwave) is located at the arteriotomy. In some embodiments, the
user interface may provide a display to assist the user in
appropriately adjusting the position and orientation of the
applicator. The display may include graphical elements such as
cross hairs or target circles as well as ultrasound images of the
focal region. Those of skill in the art will appreciate many
possibilities for providing feedback to a user to assist in
aligning a therapeutic energy source with the arteriotomy locating
sensor on the Targeting Catheter.
[0122] FIG. 11 illustrates the applicator 20 positioned over the
arteriotomy with the targeting catheter positioned such that the
arteriotomy locating beacon 36 are positioned at the centroid of
the arteriotomy. Waves 74 depicted in the illustration represent
acoustic energy from the beacon 36 in which the ATOF measurement is
performed via acoustic sensors on the therapeutic array located on
the applicator 20. FIG. 12 illustrates one embodiment of a user
interface 78 for targeting on the arteriotomy. The circle/bullseye
80 represents the position of the focal point of the therapeutic
applicator and the cross hair 82 represents the location of the
arteriomety locating sensor as determined by ATOF. The user may be
instructed to align the bullseye on top of the crosshairs thereby
insuring that the arteriotomy is within the focus of the
therapeutic applicator.
[0123] Target localization based on acoustic time of flight (ATOF)
can provide accurate and robust position sensing of target location
relative to the therapeutic ultrasound transducer. Direct X, Y and
Z (i.e. three-dimensional) coordinate locations of the target can
be provided without the need for image interpretation.
Three-dimensional targeting information facilitates the use of an
explicit user interface to guide operator actions. ATOF is less
sensitive to variations in patient anatomy as compared to imaging
techniques. ATOF can be accomplished with a relatively simple and
inexpensive system compared to the complex imaging systems used by
alternate techniques. In some embodiments, continuous tracking of
the target in the presence of movement between the target and the
external transducer may be provided. In some embodiments, ATOF
allows use of system architectures that utilize a larger fraction
of the patient contact area to generate therapeutic power (as
contrasted with imaging based alternatives)--thus reducing the
power density applied to the patient's skin.
[0124] FIG. 13 illustrates one embodiment of an ATOF system that
includes a beacon 36 having a small ultrasonic transmitter 36 such
as described above placed at or near the arteriotomy site 33 (e.g.,
through use of a targeting catheter). An array of ultrasound
receiver sensors 92 generally encircling the outer diameter of the
ultrasound therapeutic transducer 90 is located on the applicator.
The in-situ transducer (beacon) 36 is pulsed while simultaneously
the receivers 92 begin to listen for the ultrasound pulses to
arrive. Each of the receivers 92 independently measures the time
for the pulse to reach their location. The time of flight from the
receiver 92 to the beacon 36 can be determined and the location of
the beacon 36 can be calculated by using a variety of triangulation
techniques familiar to those skilled in the art of sonomicrometry
and/or global positioning systems (GPS). The historical basis for
this approach is partially documented in U.S. Pat. No. 4,154,114 to
Katz and in U.S. Pat. No. 4,100,916 to King. Veseley, in U.S. Pat.
No. 6,019,725, provides a good description of 3D tracking. All of
these patents are incorporated herein by reference in their
entirety.
[0125] It should be recognized that while embodiments will be
described wherein the beacon 36, as described above, transmits and
the receivers 92 receive, the transmit and receive functions may be
reversed or used in configurations wherein various or all sensors
both transmit and receive.
[0126] It should also be recognized that it may be advantageous to
provide for higher accuracy of position determination at and in the
vicinity of the therapeutic target, while permitting lower
resolution in locations off target. Such lower resolution may be
adequate for providing navigation (positioning of the therapy
transducer on the patient) guidance to the operator.
[0127] The transmitting beacon 36 may be "pinged" with a short
burst of approximately 3 cycles. The frequency of the ultrasound
burst requires a tradeoff between location sensitivity, signal
attenuation, and dispersion angle. Higher frequencies help to
improve the accuracy of the location data. At lower frequencies the
signal may encounter less attenuation its path to the receivers 92,
which will generally produce a better signal to noise ratio. Also
at lower frequencies, the transmitter will tend to distribute its
energy over a wider angle for given transducer dimensions, which
will allow the beam to spread out over a wider area to better reach
the receivers 92 from a variety of locations in the targeting
space. For an arteriotomy locator, in one embodiment, a frequency
in the range of about 500 KHz to about 1 MHz is used, providing
good resolution, low attenuation, and compatibility with isotropic
transducers that can be inexpensively fabricated.
[0128] As noted above, the receiving sensors 92 may be placed in an
array, or constellation, around the therapeutic transducer 90. A
minimum of three elements may be used to allow the position of the
beacon 36 to be calculated in 3 dimensions. Additional sensors can
be used to improve the accuracy, robustness and sensitivity of the
calculation. The analog signal from the receivers may be, after
pre-amplification, converted to digital format for accurate signal
processing. The rate at which the signal is digitized may influence
the maximum accuracy, or precision, of the time of flight
calculation. The precision is determined by the speed of sound in
human tissue, which is approximately 1540 meters/second, and the
rate at which digital samples are collected as follows.
Distance_per_sample (m)=speed_of_sound (m/s)/samples_per_second
(1/s) Eq. A For example, if the signal is digitized at 32 million
samples per second, the precision of the measurement due to
sampling will be 1540/32,000,000=0.048 millimeters.
[0129] The timing of the transmit pulse and the collection of data
from the receivers 92 may be synchronized by controller electronics
so that the time of flight can be measured. The receivers 92 can
start counting samples at the same time the transmit burst begins.
Each channel will then continue to count until it detects the
arrival of the short ultrasound burst. Although the burst may be
many digital samples in length, a specific sample within the
received burst can be chosen as the "official" arrival time in
order to achieve maximum accuracy.
[0130] There are several possible algorithms that the receivers 92
can employ to determine when they have detected the arrival of the
ultrasound pulse. For example, detection of the peak amplitude of
the received signal, correlation with the expected pulse shape, or
first crossing of an amplitude above the noise floor could all
produce a specific sample number that would be used as the
detection point for arrival of the burst. While the sampling rate
of the received signal may determine the precision of the
measurement, the detection algorithm can influence the
measurement's accuracy.
[0131] The size of the volume in which the beacon 36 can be
detected will determine several design parameters of the system.
For example, if the detection volume is a cylinder whose circular
diameter is equal to the diameter of the ring of receivers 92
around the transducer 90 (a representative case for vascular
sealing) and whose depth is the maximum depth of the arteriotomy
then several parameters can be known. These dimensions define the
maximum time over which the receiver's TOF detectors 92 must
operate. This volume, along with the attenuation of the ultrasound
signal in tissue at the chosen frequency will also determine the
power required from the beacon and the sensitivity required from
the receivers 92. For example, if the diameter of the ring of
receivers 92 is 45 mm and the maximum depth required is 50 mm then
the maximum distance from the beacon 36 to the farthest receiver
will be: Sqrt(45.sup.2+50.sup.2)=67.25 mm Eq. B The maximum time of
flight will be: 0.06725 m/1540 m/s=43.67 microseconds
[0132] When the time of flight to each receiver 92 is known and the
time has been converted to a distance between the beacon 36 and the
receiver 92, then the position of the beacon 36 relative to the
receivers 92 can be calculated. A minimum of three receivers 92 can
be used to calculate the X, Y and Z position of the beacon 36. If
more than three sensors are available the accuracy of the position
calculation can be improved in a number of ways. For example, if
four sensors are available then the position can be calculated four
times with different combinations of three sensors and the results
could be averaged. Or, if more than three sensors are available,
extra weight could be given to those with the best signal as
determined by received amplitude or sharpness of the correlation
result. These techniques are explained in more detail below.
[0133] To calculate the position of the beacon 36, a three
dimensional coordinate system is defined within the space where the
beacon 36 may lie relative to the receivers. In the application
with the therapeutic transducer 90, the ring of receivers 92 would
conveniently lie in the X,Y plane at the zero crossing of the Z
axis (planar constellation of receivers 92). The Z axis extends
into the body, perpendicular to the face of the transducer 90 and
passes through the center of therapy. The coordinates of the beacon
36 can be calculated by solving a system of three equations with
three unknowns. Let x.sub.i, y.sub.i and Z.sub.i be the coordinates
of the receivers 92 in the three dimensional coordinate space where
i=1 through 3. Let d.sub.i equal the distance from the receiver 92
to the beacon 36 based on the time of flight measurements. Let
X.sub.b, Y.sub.b and Z.sub.b be the coordinates of the beacon 36.
Then,
(X.sub.b-x.sub.i).sup.2+(Y.sub.b-y.sub.i).sup.2+(Z.sub.b-z.sub.i).s-
up.2=d.sub.i.sup.2 (for i=1 through 3) Eq. C
[0134] There are a number of ways to solve eq. C well know to those
skill in the art. These methods are discussed in greater detail
below. Solutions that are computationally efficient are preferred,
potentially allowing higher rates of position determinations and/or
more computational time for other system functions.
[0135] In some embodiments, sensors, or transducers, for ATOF
systems function with wide, and to the extent possible, uniform
angular sensitivity so that pulses may be effectively sent and
received to and from a variety of locations in the targeting space.
In vascular sealing, where the transmitting beacon is mounted on a
targeting aid positioned in the entry channel, a range of angular
orientations with respect to the receiver constellation results
from the fact that entry channels are inclined at various angles to
the skin surface. These angles are typically between 30 and 70
degrees.
[0136] For such isotropy, transducers generally can be small with
respect to the dimensions of their acoustic wavelength (e.g., less
than one-half wavelength). Transducers are also preferably
dimensionally small so that the phase difference (or time delay)
across the sensor is small; a large phase difference will distort
an accurate time measurement.
[0137] Transducer Materials: Materials for ATOF receivers and
transmitters may generally be any of the materials used in
diagnostic imaging. Because either transmit (here in the case of
beacons on the targeting aid) or receive (in the case of the
constellation of sensors) is, in many of the embodiments described
here, the only function required, material selection may be
optimized for specific transmit or receive characteristics.
[0138] Materials with various desirable characteristics may include
but are not limited to: [0139] PZT (lead-zirconate-titanate),
readily, economically available in may forms. Efficient in both
transmit and receive. [0140] PMN (lead-meta-niobate) similar to PZT
[0141] PVDF and copolymer film piezo-materials are inexpensive and
can be formed in very small shapes; these are sensitive receivers.
When used as a beacon, they can include sufficeint insulation and
isolation to shield patients from the high voltages used. [0142]
MEMS transducers (PMUTs and CMUTs) can be attractive because of
their wide bandwidth, and potentially low cost. [0143] Barium
titanate and other suitable materials.
[0144] Transducer Shapes: A variety of transducer shapes may be
used. Optimum configurations differ generally depending upon
whether the transducer is mounted on the targeting catheter or
those mounted on the applicator, viz the constellation. For the
targeting catheter beacon, cylindrical piezoceramic elements may be
used and offer a number of advantages. FIG. 14 depicts use of a
cylindrical element having multi-mode characteristics. A hollow
cylindrical transducer 120 has electrodes inside and outside, thus
applying a field across the thickness of the cylinder's wall.
Several vibrational modes may be selectively driven by selection of
drive frequency. Lateral (or radial) mode 122 is the hoop mode;
lateral mode 124 is the wall thickness mode; and length mode 126
radiates forward as shown. Frequencies and uses of modes are listed
below for example purposes and are not intended to be limited to:
[0145] a) Hoop Mode (0.75 MHz): [0146] ATOF: Beacon Position
Tracking, Station Keeping [0147] T/R Doppler: Arteriotomy Position
Locating [0148] b) Wall Thickness Mode (8.5 MHz) (Side View) [0149]
PW Doppler: Arteriotomy Position Locating [0150] T/R Doppler:
Arteriotomy Position Locating [0151] c) Length Mode: (4.0 MHz)
[0152] PW Doppler: Arteriotomy Position Locating, Station
Keeping
[0153] Cylindrical transducers may also advantageously be used in
multiples, where for example, two transducers are mounted on the
distal end of a targeting aid to make up the beacon. More
information regarding use of two-transducer configurations may be
found in U.S. Pat. Nos. 5,515,853; 4,407,294; and 4,697,595, all of
which are incorporated herein by reference in their entirety.
[0154] Spherical or partial-sphere shaped transducers also have
advantages of excellent isotropy for beacon/TA applications. These
transducers also present smooth, rounded surfaces compatible with
insertion into the body. Alternatively, greater isotropy may be
realized by operating the transducers at multiple frequencies where
the nulls of the radiation pattern at one frequency are
complimented by non-null sensitivity at another frequency.
[0155] For transducers used in the applicator mounted constellation
and operated as receivers, planar structures may provide
fabrication advantages and provide a substantially flat surface
that readily couples to the patient's skin surface. It is noted
that, for vascular sealing applications where the axis of therapy
is approximately centered in the targeting space, high resolution
of spatial localization of the targeting catheter is only needed in
the vicinity of the center. Away from the center only rough
estimates of targeting catheter are needed in order to provide the
operator directional movement information. FIG. 15 depicts one
embodiment of an applicator face having ATOF transducers located
around the periphery, therapeutic transducers located in concentric
circles, and a CW/PW Doppler transducer located at the center.
ATOF Distance/Position Computation
[0156] Problem: Find the (X, Y, Z) coordinates of a transmitter
given the spatial coordinates of N receivers (e.g., N=8) and the
distance measurements from each one. Let Xi, Yi, Zi be the receiver
coordinates and Di the measured distances, where i=1 . . . N. In
the case of a planar applicator face (see FIG. 15), all Zi are
equal, since the receivers are coplanar. Let Zi=Z.sub.0 for all
i.
[0157] Solution based on three receivers: A solution for (X, Y, Z)
can be found using any three receivers, denoted here as 1, 2 and 3.
The receivers are coplanar and arranged in a ring with 45 degree
angles between them. The receiver closest to the projection of the
transmitter onto the receivers plane can be denoted as receiver
(1). The other two (2, 3) are the farthest from the projection,
i.e. in an angle of 135 degrees from (1) in both directions.
Receiver (1) may have the strongest signal.
[0158] The coordinates of the three receivers are: (X.sub.1,
Y.sub.1, Z.sub.0), (X.sub.2, Y.sub.2, Z.sub.0) and (X.sub.3,
Y.sub.3, Z.sub.0), respectively. The corresponding distance
measurements are D.sub.1, D.sub.2 and D.sub.3. Assuming no error in
the measurements, the following three equations can be solved for
(X, Y, Z):
(X-X.sub.1).sup.2+(Y-Y.sub.1).sup.2+(Z-Z.sub.0).sup.2=D.sub.1.sup.2
(X-X.sub.2).sup.2+(Y-Y.sub.2).sup.2+(Z-Z.sub.0).sup.2=D.sub.2.sup.2
(X-X.sub.3).sup.2+(Y-Y.sub.3).sup.2+(Z-Z.sub.0).sup.2=D.sub.3.sup.2
(1)
[0159] These three quadratic equations reduce to two linear
equations with unknowns (X, Y) if the first equation is subtracted
from the second and the second from the third. The resulting
equations are: 2(X.sub.2-X.sub.1)X+2(Y.sub.2-Y.sub.1)=b.sub.1
2(X.sub.3-X.sub.1)X+2(Y.sub.3-Y.sub.1)=b.sub.2 (2) where,
b.sub.1=D.sub.1.sup.2-D.sub.2.sup.2+X.sub.2.sup.2+Y.sub.2.sup.2-X.sub.1.s-
up.2-Y.sub.1.sup.2
b.sub.2=D.sub.2.sup.2-D.sub.3.sup.2+X.sub.3.sup.2+Y.sub.3.sup.2-X.sub.2.s-
up.2-Y.sub.2.sup.2
[0160] These two equations can easily be solved for (X, Y). Z can
then be found from any of the original three equations (a quadratic
equation with one unknown).
[0161] Solution based on N receivers: The solution for N receivers
involves an iterative minimization process of an objective function
that is based on the sum of square errors from the receivers and
can be formulated as follows: J(X,Y,Z)=.SIGMA.(Di-Li).sup.2 where
is over all receivers i=1 . . . N, Di is the measured distance from
the transmitter to the i.sup.th receiver, and: Li=
(X-X.sub.i).sup.2+(Y-Y.sub.i).sup.2+(Z-Z.sub.i).sup.2 is the
Euclidian distance from the transmitter location (X, Y, Z) to be
found to the i.sup.th receiver. Note that no assumptions are made
on the coplanarity of the receivers (i.e. the Z.sub.i are not
necessarily equal).
[0162] Partially differentiating J(X, Y, Z) with respect to X, Y, Z
gives the following three equations:
.differential.J/.differential.X=.SIGMA.2(Di-Li)(Xi-X)/Li
.differential.J/.differential.Y=.SIGMA.2(Di-Li)(Yi-Y)/Li
.differential.J/.differential.Z=.SIGMA.2(Di-Li)(Zi-Z)/Li (3)
Equating each of these equations to zero, yields:
X=.SIGMA.[Xi+Di(X-Xi)/Li]/N Y=.SIGMA.[Yi+Di(Y-Yi)/Li]/N
Z=.SIGMA.[Zi+Di(Z-Zi)/Li]/N
[0163] The expressions (X-Xi)/Li, (Y-Yi)/Li and (Z-Zi)/Li are the
cosine of the angles between the transmitter and i.sup.th receiver
and its projection into the Y-Z, X-Z and Y-Z planes respectively.
Therefore, the above equations can be written as: X=.SIGMA.[Xi+Di
Cos(.theta..sub.YZ)]/N Y=.SIGMA.[Yi+Di Cos(.theta..sub.XZ)]/N
Z=.SIGMA.[Zi+Di Cos(.theta..sub.YZ)]/N (4)
[0164] The angles depend on the transmitter location (X, Y, Z).
However, to a good approximation, it can be assumed that these
angles will not vary by much between iterations. Therefore the
angles from the (k-1).sup.th iteration can be used in the k.sup.th
iteration.
[0165] The algorithm can be stated as follows: [0166] 1. Choose
initial conditions for the transmitter location (X, Y, Z). This can
be done using any three receivers, for example as shown in Part 1.
[0167] 2. Calculate initial Li, i=1 . . . N and the initial
objective function J(X, Y, Z). [0168] 3. Repeat K times with
iteration counter k=1 . . . K: [0169] a. Calculate Li, i=1 . . . N
and the objective function J(X, Y, Z) [0170] b. If the absolute
value of the difference between J in the (k-1).sup.th iteration and
the k.sup.th (current) iteration is less than .epsilon., stop.
[0171] c. Calculate the cosine angles Cos(.theta..sub.YZ),
Cos(.theta..sub.XZ) and Cos(.theta..sub.YZ) based on the last
iteration. [0172] d. Update the transmitter location (X, Y, Z)
based on equations (4). [0173] 4. End iteration loop.
[0174] Returning to the discussion of the flow chart in FIG. 5, at
block 108, after aligning the applicator using the beacon, the user
may apply additional hemostatic compression with the applicator so
as to transiently either partially or fully occlude the artery. By
temporarily reducing or completely stopping blood flow, less energy
required to be delivered at the arteriotomy to perform thermal
hemostasis, since vessel blood flow serves to dissipate focused
delivery of energy. During compression, care may be taken to
maintain accurate targeting.
[0175] The use of additional transducers and sensors may be used to
aid in compression measurement feedback to the user. An example of
such transducers and sensors may include a Doppler transducer and a
force sensor, each located in the applicator, to continuously
interrogate the vascular blood flow and the applied compressive
force, respectively. A compression algorithm resident in the
generator may be used to analyze signals from the sensors and
produce graphical feedback on the applicator display to enable the
user to apply and maintain adequate compression of the arteriotomy
(see compression indicator in FIG. 12). Alternatively or in
addition to these sensors, a sensor capable of monitoring blood
flow and artery pressure properties may be located on the targeting
catheter. Non-limiting examples of such a sensor include Doppler
ultrasound sensors, an optical fiber sensor, thermal sensors, or
other pressure/flow sensors used to monitor blood flow
characteristics. Pressure sensors attached to the therapeutic
transducer can be calibrated with respect to the blood flow sensors
located in the artery on the targeting catheter. Upon removal of
the targeting catheter, the pressure sensors located on the
therapeutic applicator can be used to determine the status of the
vessel (e.g. unobstructed, partially occluded, or fully occluded).
Additionally, external blood flow/pressure sensors may also be used
such as traditional manual stethoscope in combination with the
application of pressure
[0176] FIG. 7E illustrates the applicator 20 applying force against
the tissue 31 causing the vessel 28 to transiently be either
partially or fully occluded. The reasons for applying pressure are
to stop the bleeding occurring at the wall puncture site prior to
(as described above) and during the application therapeutic energy
dose. Additionally, by reducing or eliminating blood flow through
the vessel 28, efficient delivery of thermal energy to cause
hemostasis is promoted, since vessel blood flow serves to dissipate
the delivered thermal energy.
[0177] It is has been discovered that one can improve the
efficiency of thermal energy vascular closure by administering the
thermal energy (e.g. high intensity focused ultrasound) under
conditions whereby all tissue blood flow related convective cooling
can be eliminated; specifically bleeding which occurs in the
introducer track and from the arterial (luminal) blood flow.
Accordingly, one embodiment involves applying the therapeutic
applicator with pressure of sufficient magnitude to cause the
artery to be temporarily occluded during the dose (power-on) period
of the thermal energy and perhaps continuing for a short period
during all, or a portion of, the post-dose compression period. This
treatment condition is termed "transient arterial occlusion"
(TAO).
[0178] The following experiments were undertaken in order to
demonstrate that the delivery of thermal dose in combination with
TAO surprisingly did not adversely cause the lumen to be
permanently occluded (e.g. the interior walls of the artery to be
welded shut). FIG. 50 illustrates a testing device used to evaluate
if thermal energy in combination with TAO causes the intimal walls
of the artery to weld together. FIG. 50 illustrates bovine carotid
550 with a needle puncture arteriotomy pressed between two aluminum
plates 555. The plates are compressed together using spring clamps
560 and aligned with alignment pins 570. Compression force was
measured at 25 lbs. A thermocouple 565 was located within the
transiently occluded bovine artery. This test apparatus was then
fully submerged in boiling saline for 1 minute. The temperature and
time were chosen to exceed the temperature and equal the time
exposure that occurs during one embodiment of delivering high
intensity focused ultrasound for arterial hemostasis (e.g.,
70.degree. C. and 40 seconds, respectively). FIG. 51 is a
photograph of the bovine carotid sandwiched between the two
aluminum plates after a 60 second submersion in boiling saline.
[0179] FIG. 52 is a graph of the measured temperature from the
thermocouple located within the TAO during the time in which the
apparatus was submerged in boiling saline. The temperature of the
bovine artery reached 70.degree. C. (a targeted temperature at
which the native perivascular collagen is denaturaized and forms an
extensive fibrin network that covers the arteriotomy) within 11
seconds and then equilibrates to 100.degree. C. within 40 seconds.
The temperature of the boiling saline bath was measured but
remained constant at 100.degree. C. Upon removal of the apparatus
from the boiling saline, the spring clamps and aluminum plates were
removed and the artery was cut in order to inspect the lumen to
observe if any portion of the intimal surface was welded together.
As illustrated in FIG. 53 the artery springs opened after being cut
indicating that there was no occurrence of tissue welding during
TAO and thermal dosing. Lastly, the bovine artery was pressure
tested to evaluate the strength of the sealed arteriotomy. The
artery was submerged in room temperature saline and fully
pressurized with air and the pressure was recorded while being
increased until the air leaked through the arteriotomy. Table 3
illustrates the results of the destructive sealed arteriotomy
pressure testing. Over seven experiments, the intimal surface of
the arteries did not weld shut and the arteriotomy was sealed and
successfully pressure tested up to at least 3 psi. TABLE-US-00001
TABLE 3 Pressure and welding testing of bovine arteries under TAO.
Pressure resistance Time occluded Artery Welded? of arteriotomy
seal above 70.degree. C. 1 No 3 psi (155 mmHg) 49 sec 2 No >4
psi (207 mmHg) 46 sec 3 No >4 psi (207 mmHg) 50 sec 1 No 3.3 psi
(171 mmHg) 47 sec 2 No >5 psi (259 mmHg) 53 sec 3 No >4 psi
(207 mmHg) 49 sec 4 No >5 psi (259 mmHg) 49 sec
[0180] By monitoring the blood flow levels in the artery 28 while
measuring the applied pressure, one can determine the optimal
applied pressure and thereby maintain this pressure throughout the
procedure. FIG. 12 is an illustration of one possible user
interface that displays the amount of therapeutic applicator
compression 120 applied by the user. The desplay may be coupled to
the blood flow sensor to provide an indication of blood flow and
hence compression. This user interface may be continually viewed by
the user to insure proper compression is applied by the therapeutic
applicator.
[0181] In one embodiment, the pressure sensing capability of
piezoelectric material in the ultrasound transducers located on the
applicator may be used to monitor the presure applied by the
applicator. This method gives a direct measurement of the pressure
at the surface of the applicator. This pressure can be correlated
with typical pressures required to stop puncture track blood flow,
maintain artery patency, partially occlude the artery, or fully
occlude the artery. In other embodiments described above, the
pressure may be monitored by sensors located on a targeting
catheter (e.g., piezoelectric sensors that measure blood flow using
Doppler effects).
[0182] The amount of pressure at the surface of the applicator
transducers can be detected using impedance changes within the
piezoelectric elements or a change in voltage at the element. This
technique allows detection of pressure directly at the applicator
face. In addition, uneven pressure may be detected by separately
making measurements from multiple elements at different spatial
locations. By using the existing piezoelectric elements in the
therapeutic ultrasound array, no additional materials need to be
added. Pressure at the surface of the applicator can be correlated
to the occlusion status of the vessel and to the compression
required to stop blood flow up the introducer track. The existing
capability in the generator may be used to monitor power, voltage,
current and phase.
[0183] Piezoelectricity is a property of certain classes of
crystalline materials including natural crystals of Quartz,
Rochelle Salt and Tourmaline as well as manufactured ceramics or
polymer films such as Lead Zirconate Titanates (PZT) and
polyvinylidene fluoride. When an electric field is applied to the
materials, the material deforms depending on the orientation.
Conversely, when a stress is applied, an electric field is produced
in the material.
[0184] In one embodiment, the applicator design uses PZT to produce
an ultrasound wave when excited electrically. Since PZT is a
synthetic crystal structure, the material is naturally isotropic
and therefore non-piezoelectric. PZT must go through a poling
process where a high voltage is applied at elevated temperatures to
orient the net effect of the material domains in one direction.
During the poling process, the material expands in the direction of
the electric field.
[0185] After the PZT has been poled, expansion or contraction of
the material will create a build-up of charge at the poling
electrodes. If the compression force is in the poling direction,
then the voltage polarity detected is the same as the poling
voltage. If a tensile force is applied, then the voltage polarity
detected is the opposite of the poling voltage.
[0186] This piezoelectric effect can be used to detect the amount
of pressure at the surface of the transducer. The magnitude of the
voltage is related to the receiving constant (g) of the
piezoelectric material as well as the magnitude of the stress
applied (T) and thickness of the ceramic (t). V.sub.oc=g*T*t (eq.
8) where V.sub.oc is the open circuit voltage received at the
element. Therefore, if a resistive load is connected to the
terminals of the device, the charge created would be electrically
dissipated. The shape of the signal at the piezoelectric element is
dependent on the impulse of the stress and the time constant with
the load. The amount of charge on the device is dependent on the
voltage and element capacitance.
[0187] In order to test the significance of this effect, an Antares
VF10-5 transducer (Siemens A G, Munich, Germany), 10.times. probe,
and oscilloscope was used to detect the voltage produced by a
stress. One element in the VF10-5 transducer was connected to the
10.times. probe. The 10.times. probe was connected to a Tektronix
oscilloscope (Tektronix, Inc., Beaverton, OR) that was set for a
single shot trigger. The transducer face was then pressed onto a
hard surface and released. Similarly, the transducer face was
pressed with a thumb and released. FIGS. 16 and 17 show the
magnitude of the voltage detected. Since the charge on the
transducer element is being dissipated through the 10.times. probe,
the shorter the impulse, the larger the voltage signal detected.
Overall, voltages above 20 mV were detected in this experiment
(FIGS. 16 and 17). This is significant given the overall small
element size (approximately 150 um wide by 5 mm tall) and long
coaxial cable (2.1 m) between the element and 10.times. probe.
[0188] Although the experiment with the VF10-5 showed that pressure
changes were detectable, the magnitude detected is dependent on
impulse signal created by the impulsive load delivered.
[0189] Next, an experiment was conducted to detect the impedance of
the therapeutic elements with and without a pressure at the face. A
therapeutic applicator was placed in a water bath and a low voltage
(3 V) CW signal at 2 MHz from the generator excited the elements of
the transducer. The power, voltage, current and phase were
monitored. Next, pressure was applied to the face of the transducer
and the variables were again monitored. Phase changes on the order
of 10 degrees were detected when the pressure was applied. Since
the current and voltage waveforms were more in-phase with the
application of a compressive stress, the power increased. A force
balance can be applied to determine the relationship between
pressure magnitude and amount of phase change.
[0190] Another means to monitor the status of the a vessel (open,
partially occluded or fully occluded) is to use an acoustic Doppler
system placed onto the patients skin to analyze vessel wall Doppler
sounds to provide an indication of "proper" compression levels and
on-location feedback. This measurement is useful since the
compression of the artery will affect the Doppler sounds obtained
from a transducer that is mounted perpendicular to the flow even
though there is no flow signal. Turbulence and wall motion will be
present which will yield different Doppler signals than when the
arteries is either fully open or fully collapsed.
[0191] Returning to the discussion of the flowchart in FIG. 5, at
block 110, after the desired level of compression is applied, a
station keeping method can be initiated to maintain proper
alignment of the applicator during therapy. Subsequent to
alignment, the targeting catheter continues to reside in the
puncture tract with the beacon being proximate to the arteriotomy.
The application of therapeutic energy may be applied at this point,
however, in some embodiments, the procedure involves removing the
targeting catheter from the arteriotomy location (discussed in more
detail below). Removing the targeting catheter allows for the most
effective acoustic hemostasis. In some embodiments, methods are
provided to ensure that the therapeutic applicator stays focused
upon the arteriotomy in the absence of the beacon. In anticipation
of the targeting catheter being removed, a station keeping method
may be initiated as illustrated in FIG. 7F. Station keeping, which
is described in detail below, may be used to track tissue 31 motion
(e.g., specifically the arteriotomy 30 or tissue proximate to it)
using acoustic waves with radio frequency signal processing
techniques (referred to herein as RfUME (Radio Frequency Ultrasound
Motion Estimate)). Specifically, at least three acoustic
transducers, pistons, or arrays may be used to track the motion of
a common point. Movement may be determined by comparing a reference
signal to a present signal. The difference between the signals
determines the amount of movement of the tissue 31 relative to the
transducers and hence relative to the applicator 20.
[0192] Accordingly, in anticipation of removing the targeting
catheter 32, the ATOF targeting of the arteriotomy targeting aid 34
and beacon 36 may be replaced by station keeping of the arteriotomy
site 30. This station keeping information may be displayed to the
user through the same targeting user interface as depicted in FIG.
12. This display provides feedback to a user so that the user can
maintain the focus point of the therapeutic energy applicator 20 at
the site of the arteriotomy 30.
[0193] The purpose of station keeping is to track tissue motion. In
one embodiment, at least three transducers may be used to track the
motion of a common point. The motion may be tracked using a variety
of techniques including traditional pulse-echo techniques as well
as a pitch-catch sequence. The pitch-catch algorithm has several
advantages when compared with conventional pulse-echo techniques.
The acquisition time required to determine the motion is
significantly reduced, thereby reducing the susceptibility to
jitter, allowing the system to see faster movements, and allowing
more time for therapy if interleaving is used. In addition, a
greater amount of redundancy is achieved in less acquisition time
for improved motion estimation. If the pitch-catch technique is
allocated the same acquisition time as the conventional approach,
the SNR of each acquisition is also increased, thereby increasing
penetration and improving tracking ability. Finally, system
complexity is reduced by reducing hardware requirements (e.g.
transmit-receive switches).
[0194] The overlapping beam pattern of at least three ultrasound
transducers can be used to track the motion in three dimensions. In
this case, a unit vector from the transducer to the coordinate
system of the interrogated point describes the beam direction and
sensitivity to specific types of movement. If the interrogated
point moves relative to the transducer, then a certain amount of
movement will be detected by each transducer depending on the unit
vector. In this case, the amount of motion detected at one
transducer is described as: motion.sub.k=a.sub.kx.delta.x
+a.sub.ky.delta.y+a.sub.kz.delta.z (9) where .delta..sub.x,
.delta..sub.y, and .delta..sub.z are the small movements of the
point from the original position in three dimensions, and a.sub.kx,
a.sub.ky, and a.sub.kz are the unit vector components for the
k.sup.th transducer. The amount of motion can be calculated by
measuring the amount of movement from at least two other
transducers and realizing that the motion detected in ultrasound is
related to a time shift: motion k - t k c tissue 2 ( 10 ) ##EQU1##
where t.sub.k is the time difference between the first signal and
the next signal, and c.sub.tissue is the velocity of sound in
tissue. The factor of two occurs in equation (10) due to the time
required for the ultrasound pulse to travel out and back from the
interrogation point. The time difference t.sub.k is determined by
fitting a previous or reference pulse to the current pulse. A
correlation technique is typically used to determine the best fit.
Therefore, the system can be described by combining equations (9)
and (10) to obtain: [ t 1 t 2 t 3 ] = 2 c tissue [ a 1 .times. x a
1 .times. y a 1 .times. z a 2 .times. x a 2 .times. y a 2 .times. z
a 3 .times. x a 3 .times. y a 3 .times. z ] [ .delta. .times.
.times. x .delta. .times. .times. y .delta. .times. .times. z ] (
11 ) ##EQU2##
[0195] If the time differences are known as well as the unit
vectors given the system configuration, then the amount of motion
can be determined. If the system has multiple transducers, then
redundancy exists in the system and multiple solutions can be
calculated.
[0196] In the pitch-catch approach, instead of transmitting and
receiving on the same transducer, energy is transmitted by only one
transducer and the backscatter is detected by the other
transducers. For example, if a three transducer system is used, the
transmit event might occur on transducer 1 with transducer 2 and 3
detecting the backscatter. A second transmit might occur on
transducer 2 with transducer 1 and 3 detecting the backscatter. In
this case, the motion detected is a combination of the unit vectors
from the transmit and receive transducers.
motion.sub.k=(a.sub.kx+a.sub.mx).delta.x+(a.sub.ky+a.sub.my).delta.y+(a.s-
ub.kz+a.sub.mz).delta.z (12) where the directional vector is the
summation of the unit vector components for the k.sub.th and
m.sub.th transducers. Another interesting result of equation 12 is
the lack of identification of the transmit and receive transducers.
In other words, reciprocity exists in equation (12). The k.sub.th
transducer could either be the transmitter or receiver and the
motion detected is the same amount.
[0197] Similar to the conventional pulse-echo approach, the amount
of motion detected is related to the time shift in the receive
pulse. However, in this case the factor of two is eliminated
because the pulse is not going out and coming back; rather it is
detected by the path between the transmitter and receiver which is
already represented in the directional vector.
motion.sub.k=t.sub.kC.sub.issue (13)
[0198] Equations (12) and (13) can be combined to show the
relationship between the time shift and the motion of the
interrogation point. [ t 1 t 2 t 3 ] = 1 c tissue [ ( a 1 .times. x
+ a 2 .times. x ) ( a 1 .times. y + a 2 .times. y ) ( a 1 .times. z
+ a 2 .times. z ) ( a 1 .times. x + a 3 .times. x ) ( a 1 .times. y
+ a 3 .times. y ) ( a 1 .times. z + a 3 .times. z ) ( a 2 .times. x
+ a 3 .times. x ) ( a 2 .times. y + a 3 .times. y ) ( a 2 .times. z
+ a 3 .times. z ) ] [ .delta. .times. .times. x .delta. .times.
.times. y .delta. .times. .times. z ] ( 14 ) ##EQU3##
[0199] In this case, the transmit might occur on transducer 1 and
detection on transducers 2 and 3. This would yield t.sub.1, and
t.sub.2. A second transmit might occur on transducer 2 and
detection could occur on transducer 1 and 3. In this case, t.sub.1,
and t.sub.3 are determined; however, note that only t.sub.3 is
required to allow for equation (14) to be solved for the movement.
The extra t.sub.1 measured time could be used to improve the
estimate (SNR) or just discarded.
[0200] Compared to the conventional approach, only two transmit
events are required to solve for the movement in equation 14.
Therefore, the amount of time to acquire and calculate a movement
has decreased by 33%. This extra time can be used to increase the
acquisition rate and detect faster movements. This extra time may
also be dedicated for therapy.
[0201] The pitch-catch method also has the advantage for reducing
the hardware required. For example, in the three transducer system,
two transducers require a transmit/receive architecture with the
other transducer only requiring a receive architecture. In the
conventional case, all three transducers need a transmit/receive
architecture.
[0202] In the case of more than three transducers, the pitch-catch
approach offers the possibilities of motion estimation redundancy
with only one transmit. For example, if the system has five
transducers, then transmitting on one transducer yields the
possibility of four different solutions. This redundancy allows for
better motion estimation through averaging techniques or solution
selection given the signal quality. In the conventional approach,
at least four transmit events are required for this amount of
redundancy in a five transducer system.
[0203] In some embodiments, the pulse-echo and pitch-catch approach
may be combined in a hybrid approach to yield an even faster
acquisition. In this case, equation (14) becomes: [ t 1 t 2 t 3 2 ]
= 1 c tissue [ ( a 1 .times. x + a 2 .times. x ) ( a 1 .times. y +
a 2 .times. y ) ( a 1 .times. z + a 2 .times. z ) ( a 1 .times. x +
a 3 .times. x ) ( a 1 .times. y + a 3 .times. y ) ( a 1 .times. z +
a 3 .times. z ) ( a 1 .times. x ) ( a 1 .times. y ) ( a 1 .times. z
) ] [ .delta. .times. .times. x .delta. .times. .times. y .delta.
.times. .times. z ] ( 15 ) ##EQU4##
[0204] In this case, the system has transmitted on transducer 1 and
received on all three transducers. Acquisition time is decreased by
67% when compared to the conventional approach with three
transducers.
[0205] In order to evaluate the performance of the pitch-catch
technique, a fixture with three 6 mm ultrasonic pistons was design
and tested. The fixture was coupled to an agar phantom and
pitch-catch data was acquired and motion estimation was calculated
off-line. A Panametrics 5072PR pulser was used as the transmitter
and a Metrotek MR101 receiver was used. FIGS. 18, 19 and 20 are
graphs showing the correlation between actual position and that
determined using the pitch-catch RfUME algorithm described above
for X, Y, and Z coordinates, respectively. The ideal result of
one-to-one correlation is plotted as a line of slope 1. The
distances determined using the RfUME algorithm are plotted as
circles. FIGS. 18, 19 and 20 show that after a certain amount of
movement, the algorithm stops tracking. This result is primarily
due to the beam width and the transducer directionality. For
example, improvement in tracking x and y movement can be
accomplished by widening the beam or placing the transducer at a
steeper interrogation angle such that the transducer has greater
detection of x and y movement. Although the algorithm stops
tracking after a certain amount of movement, this effect can be
avoided in real-time by referencing when required.
[0206] As discussed above, movement relative to tissue is
determined by comparing a reference signal to a present signal. The
phase difference between these signals helps determine the amount
of movement of the transducer or tissue. Unfortunately, this motion
estimation is a simplification of the actual movement. Accordingly,
such algorithms have the potential of significant error if the
transducer or tissue moves by large amounts or if the transducer is
tipped or tilted. Thus, in some embodiments, a recursive algorithm
is used to determine the movement. Results show that the recursive
algorithm tracks movement due to rotation much better than the
simplified version. The error for translational movement is also
reduced from approximately 5% to less than 2%. There are several
benefits of using the recursive algorithm approach. The motion
estimation due to elevation or roll rotation is significantly
improved, especially in the depth dimension. In addition, the
standard deviation of the motion estimation is reduced from
approximately 5% to less than 2%. No simplification of the acoustic
formulas is required to track movement. Furthermore, only a small
amount of iterations are required for the system to reach
equilibrium
[0207] In some embodiments, a conventional pulse-echo approach may
be utilized for station keeping. The overlapping beam pattern of at
least three transducers can be used to track the motion in three
dimensions. In this case, a unit vector from the transducer to the
coordinate system of the interrogated point describes the beam
direction and sensitivity to specific types of movement. If an
interrogated point moves relative to the transducer, then a certain
amount of movement will be detected by each transducer depending on
the unit vector. In this case, the amount of motion detected at one
transducer is described as:
motion.sub.k=a.sub.kx.DELTA.x+a.sub.ky.DELTA.y+a.sub.kz.DELTA.Z
(16) where .delta.x, .delta.y, and .delta.z are the small movements
of the point from the original position in three dimensions, and
a.sub.kx, a.sub.ky, and a.sub.kz are the unit vector components for
the k.sup.th transducer. The amount of motion can be calculated by
measuring the amount of movement from at least two other
transducers and realizing that the motion detected in ultrasound is
related to a time shift: motion k - t k c tissue 2 ( 17 ) ##EQU5##
where t.sub.k is the time difference between the first signal and
the next signal, and c.sub.tissue is the velocity of sound in
tissue. The factor of two occurs in equation (17) due to the time
required for the ultrasound pulse to travel out and back from the
interrogation point. The time difference t.sub.k is determined by
fitting a previous or reference pulse to the current pulse. A
correlation technique is typically used to determine the best fit.
Therefore, the system can be described by combining equations (16)
and (17) to obtain: [ t 1 t 2 t 3 ] = 2 c tissue [ a 1 .times. x a
1 .times. y a 1 .times. z a 2 .times. x a 2 .times. y a 2 .times. z
a 3 .times. x a 3 .times. y a 3 .times. z ] [ .DELTA. .times.
.times. x .DELTA. .times. .times. y .DELTA. .times. .times. z ] (
18 ) ##EQU6##
[0208] If the time differences are known as well as the unit
vectors given the system configuration, then the amount of motion
can be determined. If the system has multiple transducers, then
redundancy exists in the system and multiple solutions can be
calculated.
[0209] A recursive approach may also be used with convention
pulse-echo techniques. In the recursive approach, instead of
assuming that the unit vector from the center of the transducer to
the interrogation point completely maps the movement, a new
approach is formulated using the distance formula. For example,
assume that the transducers are in the same plane a distance `R`
from the center of a circle. In this case, the original distance to
a common interrogation point is: d io = ( R cos .function. ( 2 .pi.
N ( i - 1 ) ) ) 2 + ( R cos .function. ( 2 .pi. N ( i - 1 ) ) ) 2 +
z f 2 ( 19 ) ##EQU7## where R is the distance from the center of
the circle to the center of each transducer, N is the number of
transducers which is greater than or equal to three, i varies from
1 to N, and Z.sub.f is the distance to the interrogation point. In
this case, the interrogation point is only on the z axis. Equation
(19) simplifies to: d.sub.io= R.sup.2+z.sub.f.sup.2 (20) This
results makes sense for this system design, given that each
transducer is equidistant from the interrogation point.
[0210] If the target moves to a new point described as (.DELTA.x,
.DELTA.y, z.sub.f+.DELTA.z), where the movement can be caused by
tissue movement or transducer movement, the new distance to the
target is given as: d in = ( R cos .function. ( 2 .pi. N ( i - 1 )
) + .DELTA. .times. .times. x ) 2 + ( R sin .function. ( 2 .pi. N (
i - 1 ) ) + .DELTA. .times. .times. y ) 2 + ( z f + .DELTA. .times.
.times. z ) 2 ( 21 ) ##EQU8##
[0211] In the technique to determine motion, the phase difference
of a reference line to a current line is determined. This technique
is similar to calculating the difference between the distance
vectors. V.sub.in=d.sub.in-d.sub.io (22) where v.sub.in is the
difference between the two distances for transducer `i`.
Unfortunately, it is difficult to solve equation (22) for .DELTA.x,
.DELTA.y, and .DELTA.z because of the square root. Therefore, it
may be possible to calculate the movement if equations (20) and
(21) are first squared. d in 2 - d io 2 = ( R cos .function. ( 2
.pi. N ( i - 1 ) ) + .DELTA. .times. .times. x ) 2 + ( R sin
.function. ( 2 .pi. N ( i - 1 ) ) + .DELTA. .times. .times. y ) 2 +
( z f + .DELTA. .times. .times. z ) 2 - ( R 2 + z f 2 ) ( 23 )
##EQU9## Simplifying equation (23) yields: d in 2 - d io 2 - (
.DELTA. 2 .times. x + .DELTA. 2 .times. y + .DELTA. 2 .times. z ) 2
= R cos .function. ( .theta. i ) .DELTA. .times. .times. x + R sin
.function. ( .theta. i ) .DELTA. .times. .times. y + z f .DELTA.
.times. .times. z .times. .times. where .times. .times. .theta. i
.times. .times. is .times. .times. 2 .times. .pi. / N .function. (
i - 1 ) . ( 24 ) ##EQU10## If both sides of equation (24) are
divided by equation (20), then: d in 2 - d io 2 - ( .DELTA. 2
.times. x + .DELTA. 2 .times. y + .DELTA. 2 .times. z ) 2 R 2 + z f
2 = a ix .DELTA. .times. .times. x + a iy .DELTA. .times. .times. y
+ a iz .DELTA. .times. .times. z ( 25 ) ##EQU11## where a.sub.ix,
a.sub.iy, and a.sub.iz, are the x, y and z unit vectors from
transducer `i`.
[0212] In practice, the actual distances are not calculated from
the signal vectors, rather the time differences between the pulses
are calculated. A distance can be related to time by knowing the
speed of sound. t i = d i ( c tissue 2 ) ( 26 ) ##EQU12## If
equation (26) is substituted into equation (25), then: ( c tissue 2
) 2 ( t in 2 - t io 2 - 4 c tissue 2 .times. ( .DELTA. 2 .times. x
+ .DELTA. 2 .times. y + .DELTA. 2 .times. z ) 2 R 2 + z f 2 ) = a
ix .DELTA. .times. .times. x + a iy .DELTA. .times. .times. y + a
iz .DELTA. .times. .times. z ( 27 ) ##EQU13## Equation (27) can now
be placed into matrix form for a three transducer system: c tissue
2 8 R 2 + z f 2 [ t 1 .times. n 2 - t 1 .times. o 2 - 4 c tissue 2
.times. ( .DELTA. 2 .times. x + .DELTA. 2 .times. y + .DELTA. 2
.times. z ) t 2 .times. n 2 - t 2 .times. o 2 - 4 c tissue 2
.times. ( .DELTA. 2 .times. x + .DELTA. 2 .times. y + .DELTA. 2
.times. z ) t 3 .times. n 2 - t 3 .times. o 2 - 4 c tissue 2
.times. ( .DELTA. 2 .times. x + .DELTA. 2 .times. y + .DELTA. 2
.times. z ) ] = [ a 1 .times. .times. x a 1 .times. .times. y a 1
.times. .times. z a 2 .times. .times. x a 2 .times. .times. y a 2
.times. .times. z a 3 .times. x a 3 .times. .times. y a 3 .times. z
] [ .DELTA. .times. .times. x .DELTA. .times. .times. y .DELTA.
.times. .times. z ] ( 28 ) ##EQU14##
[0213] A recursive formula is generated by solving equation (28)
for .DELTA.x, .DELTA.y, and .DELTA.z. In this case, the calculated
motion is still a function of the distance squared. Therefore, in
order to get an initial estimate of the movement, assume that the
time differences are much larger than the sum of the square of the
movement divided by the speed of sound in tissue. In this case, the
solution is: c tissue 2 8 R 2 + z f 2 [ a 1 .times. .times. x a 1
.times. .times. y a 1 .times. .times. z a 2 .times. .times. x a 2
.times. .times. y a 2 .times. .times. z a 3 .times. x a 3 .times.
.times. y a 3 .times. z ] - 1 [ t 1 .times. n 2 - t 1 .times. o 2 t
2 .times. n 2 - t 2 .times. o 2 t 3 .times. n 2 - t 3 .times. o 2 ]
= [ 1 0 0 0 1 0 0 0 1 ] [ .DELTA. .times. .times. x .DELTA. .times.
.times. y .DELTA. .times. .times. z ] ( 29 ) ##EQU15## Also note
that: t i .times. .times. 0 2 = ( 2 c tissue ) 2 ( R 2 + z f 2 ) (
30 ) ##EQU16## This result is the initial calculation of the
movement and the estimates for .DELTA.x, .DELTA.y, and .DELTA.z can
be placed in the left side of the equation, and the motion
calculated again according to equation (31). c tissue 2 8 R 2 + z f
2 [ a 1 .times. .times. x a 1 .times. .times. y a 1 .times. .times.
z a 2 .times. .times. x a 2 .times. .times. y a 2 .times. .times. z
a 3 .times. x a 3 .times. .times. y a 3 .times. z ] - 1 [ t 1
.times. n 2 - t 1 .times. o 2 - 4 c tissue 2 .times. ( .DELTA. 2
.times. x m - 1 + .DELTA. 2 .times. y m - 1 + .DELTA. 2 .times. z m
- 1 ) t 2 .times. n 2 - t 2 .times. o 2 - 4 c tissue 2 .times. (
.DELTA. 2 .times. x m - 1 + .DELTA. 2 .times. y m - 1 + .DELTA. 2
.times. z m - 1 ) t 3 .times. n 2 - t 3 .times. o 2 - 4 c tissue 2
.times. ( .DELTA. 2 .times. x m - 1 + .DELTA. 2 .times. y m - 1 +
.DELTA. 2 .times. z m - 1 ) ] = .times. [ 1 0 0 0 1 0 0 0 1 ] [
.DELTA. .times. .times. x .times. m .DELTA. .times. .times. y
.times. m .DELTA. .times. .times. z .times. m ] ( 31 ) ##EQU17## In
this case, the index m denotes the number of times through the
calculation.
[0214] In order to determine the advantages using the recursive
formulation, data was simulated using the Field II program by
Jorgen Jensen. This allowed a phantom of random scatterers to be
easily rotated in elevation and roll. A 16 element phased array
operating at 2 MHz with 60% bandwidth was defined in Field II and
placed uniformly around a radius of 12.5 mm. The conventional
algorithm was applied to the data to determine the calculated x, y
and z motion. For example, since elevation rotation is about the
x-axis, movement is expected in the y and z dimensions. The
recursive formula was also applied to the exact same data and a
comparison was made to actual movement in x, y and z.
[0215] FIG. 21 depicts three graphs showing the actual movement
(plotted circles) in x, y and z, respectively, compared to the line
representing the calculated result using the conventional technique
(eq. 18) for rotation in elevation. In this case, the three phased
arrays are focused at a 50 mm depth. Although this algorithm
detects the y movement and lack of x movement with a high degree of
accuracy, no movement is detected in the z dimension. A similar
result is observed for roll rotation (see FIG. 22).
[0216] FIG. 23 shows the results using the recursive formula (eq.
31) for elevation rotation. In this case, the algorithm detects
accurately the motion in all three dimensions. This result only
required 10 iterations of the formula (m=10). A similar result is
observed for roll rotation (see FIG. 24).
[0217] A calibration process may be used to calibrate an ultrasound
system used to track tissue motion. The direction of the ultrasound
propagation to the focus is directly related to the amount of
detected movement. Therefore, it is advantageous to know the
direction vector from the transducers to the focus with a high
degree of accuracy. Any errors have the potential to be compounded
if re-referencing frequently. Re-referencing may be required due to
the limited region that the transducers can detect movement. The
following discussion describes a process to calibrate the direction
of ultrasound propagation from a set of transducer, pistons or
arrays. The process provides a significant reduction in potential
errors resulting in improved accuracy of motion estimation with
significantly reduced error for pistons or multi-element arrays,
increased mechanical alignment tolerances since acoustic
calibration eliminates these errors, and reduction in
susceptibility to accumulation error.
[0218] The overlapping beam pattern of at least three transducers
can be used to track the motion in three dimensions. In this case,
a unit vector from the transducer to the coordinate system of the
interrogated point describes the beam direction and sensitivity to
specific types of movement. If the interrogated point moves
relative to the transducer, then a certain amount of movement will
be detected by each transducer depending on the unit vector. In
this case, the difference in the square of distance vectors is
described as: d i .times. .times. n 2 - d io 2 = .times. ( R cos
.times. ( .times. 2 .pi. .times. N ( i .times. - .times. 1 ) )
.times. + .times. .DELTA. .times. .times. x ) 2 + .times. ( R sin
.times. ( .times. 2 .pi. .times. N ( i .times. - .times. 1 ) )
.times. + .times. .DELTA. .times. .times. y ) 2 + .times. ( .times.
z .times. f .times. + .times. .DELTA. .times. .times. z ) 2 - ( R
.times. 2 + z .times. f .times. 2 ) ( 32 ) ##EQU18## where
.DELTA.x, .DELTA.y, and .DELTA.z are the small movements of the
point from the original position in three dimensions, d.sub.in and
d.sub.io, are the new and original distance to the interrogation
point for the i.sup.th transducer, and Z.sub.f is the location of
the focus. Equation 32 also describes a system where all of the
transducers are in the same plane at a radius `R`.
[0219] Equation (32) can be simplified to: c tissue 2 8 R 2 + z f 2
[ t 1 .times. n 2 - t 1 .times. o 2 - 2 c tissue .times. ( .DELTA.
2 .times. x + .DELTA. 2 .times. y + .DELTA. 2 .times. z ) t 2
.times. n 2 - t 2 .times. o 2 - 2 c tissue .times. ( .DELTA. 2
.times. x + .DELTA. 2 .times. y + .DELTA. 2 .times. z ) t 3 .times.
n 2 - t 3 .times. o 2 - 2 c tissue .times. ( .DELTA. 2 .times. x +
.DELTA. 2 .times. y + .DELTA. 2 .times. z ) ] = [ a 1 .times.
.times. x a 1 .times. .times. y a 1 .times. .times. z a 2 .times.
.times. x a 2 .times. .times. y a 2 .times. .times. z a 3 .times. x
a 3 .times. .times. y a 3 .times. z ] [ .DELTA. .times. .times. x
.DELTA. .times. .times. y .DELTA. .times. .times. z ] ( 33 )
##EQU19## where C.sub.tissue is the velocity of sound in tissue,
t.sub.i* is the total time to the interrogation point, and a.sub.im
are the components of the unit vectors for the respective
transducers.
[0220] As equation (33) shows, solving for .DELTA.x, .DELTA.y, and
.DELTA.z requires taking the inverse of the a-matrix or directional
matrix. Therefore, it is critical to accurately determine a.sub.im
if the motion is to be tracked properly.
[0221] One method to accurately determine the directional matrix is
to mount the system in a test station that offers precise control
of x, y and z movement. Next, the system is coupled to tissue
mimicking material. The stages are moved in x, y or z only in small
increments that insures the position can be tracked. For example,
suppose that the stage is only moved in the x direction such that
.DELTA.y and .DELTA.z are zero. Equation (33) can then be
simplified to the following: c tissue 2 8 R 2 + z f 2 [ t 1 .times.
n 2 - t 1 .times. o 2 - 4 c tissue 2 .times. ( .DELTA. 2 .times. x
) t 2 .times. n 2 - t 2 .times. o 2 - 4 c tissue 2 .times. (
.DELTA. 2 .times. x ) t 3 .times. n 2 - t 3 .times. o 2 - 4 c
tissue 2 .times. ( .DELTA. 2 .times. x ) ] = [ a 1 .times. .times.
x .DELTA. .times. .times. x a 2 .times. .times. x .DELTA. .times.
.times. x a 3 .times. .times. x .DELTA. .times. .times. x ] ( 34 )
##EQU20##
[0222] Since .DELTA.x is known, equation (34) can be solved for the
x component of the unit vector: c tissue 2 8 .DELTA. .times.
.times. x R 2 + z f 2 ( t 1 .times. .times. n 2 - t 1 .times.
.times. o 2 - 4 c tissue 2 ( .DELTA. 2 .times. x ) ) = a 1 .times.
.times. x ( 35 .times. a ) c tissue 2 8 .DELTA. .times. .times. x R
2 + z f 2 ( t 2 .times. .times. n 2 - t 2 .times. .times. o 2 - 4 c
tissue 2 ( .DELTA. 2 .times. x ) ) = a 2 .times. .times. x ( 35
.times. b ) c tissue 2 8 .DELTA. .times. .times. x R 2 + z f 2 ( t
3 .times. .times. n 2 - t 3 .times. .times. o 2 - 4 c tissue 2 (
.DELTA. 2 .times. x ) ) = a 3 .times. .times. x ( 35 .times. c )
##EQU21##
[0223] Equations (35a), (35b) and (35c) show how the x components
can easily be calculated from the acquired data. By making many
.DELTA.x movements, an average and standard deviation of a.sub.1x,
a.sub.2x, and a.sub.3x can be calculated. A similar approach can be
done to calculate a.sub.iy and a.sub.iz. This technique is also not
limited to the number of transducers in the
[0224] In order to show the advantages using the calibration
procedure, data from a 4 piston was acquired at 0 degrees, 120
degrees and 240 degrees along an approximately 40 mm radius. The
piston was coupled into an agar phantom set on a three dimensional
motion stage. The phantom was separately moved in x, y and z in
0.25 mm
[0225] For the mechanical system, the directional matrix can be
calculated as in Table 1. TABLE-US-00002 TABLE 1 Calculated
original a direction matrix. X Y Z Magnitude -0.707 0.000 0.707
1.000 0.354 -0.612 0.707 1.000 0.354 0.612 0.707 1.000
[0226] FIG. 25 depicts three graphs showing the correlation between
actual position and that determined using the algorithm described
above for X, Y, and Z coordinates, pectively. The ideal result of
one-to-one correlation is plotted as a line of slope 1. distances
determined using the algorithm are plotted as points. The error
increases for large movements.
[0227] If the directional matrix is calculated using equations 35a,
35b and 35c, then the directional matrix is as indicated in Table
2. TABLE-US-00003 TABLE 2 Measured a direction matrix. X Y Z
Magnitude -0.7315 0.0116 0.8836 1.147 0.3638 -0.6372 0.6468 0.978
0.3908 0.6218 0.6487 0.980
[0228] Table 2 shows that the magnitude is not necessarily equal to
one and the components are significantly different than the
mechanical predictions. FIG. 26 depicts three graphs showing that
by using the Table 2 matrix, the algorithm results in improved
tracking of movement. For example, a 1 mm movement in the x
dimension is measured as a movement of over 1.05 mm using the
standard mechanically determined directional matrix (FIG. 25), an
error of over 5%. However, if the unit vector components are
calculated, then a 1 mm movement is measured to be 1.00 mm with an
error of less than 1% (FIG. 26). The significant reduction in error
reduces the possibility of accumulation error when re-referencing
occurs.
[0229] Some embodiments include a station keeping system for
executing the procedures described above. The system may include
multiple transducers, analog transmit and receive channels, an
optional transmit and receive beamformer, an optional multiplexer,
an analog to digital board, a CPU and memory, and an electronic
compass. In some embodiments, the system provides for the
measurement of six degrees of freedom to uniquely identify any
point in space. In some embodiments, the system is configured to
provide multiple solutions by tracking a point and calculating the
effects due to translation and rotation. In addition, in some
embodiments, the system provide for minimization of re-referencing
by storing previous reference data with the x, y and z
locations
[0230] Generally, using ultrasound for station keeping is not
sensitive to azimuth rotation unless multiple points in a plane are
tracked. Accordingly, in some embodiments, another technique may be
used to acquire the azimuth, elevation and roll angles of the
applicator at the beginning of motion estimation as well as for
future data acquisition.
[0231] FIG. 27 shows a block diagram of one embodiment of a motion
estimation system. The ultrasound transducers 200 include at least
three separate transducers that are able to point at a common
point. The transducers 200 can include pistons, linear arrays,
1.5-D arrays as well as 2-D arrays. For example, in one embodiment,
three phased arrays 202 can be used to focus at multiple points
along a central line (e.g., the Z axis) as shown in FIG. 28. In
this case, the center of each phased array 202 is a distance `R`
from the origin of the x-y coordinate system. The phased arrays 202
have length `L` and width `W` with the imaging plane bisecting the
circle 204 of radius `R`. Therefore, the phased arrays 202 track
identical points along the z-axis (out-of-the-paper). In another
embodiment, the transducers may consist only of pistons that are
mechanically pointed to a common point. This reduces the system
complexity since each piston represents only one channel.
[0232] Referring back to FIG. 27, mechanically attached to the
transducers 200 (dashed line) is an electronic compass 206 that
determines the rotation of the device prior to and during the
motion estimation. This includes azimuth, elevation and roll. The
compass 206 is used to properly track the x, y and z movement in
the coordinate system of the device away from a target.
[0233] A multiplexer 208 may be optionally included if the number
of transmit and receive channels is to be limited, for example, if
the phased arrays in FIG. 29 consist of 32 elements each. If a
multiplexer 208 is not used, a minimum of 96 transmitters and 96
receivers may be used to address each element. However, if a 3:1
multiplexer is used, then only 32 transmit and 32 receive channels
are required, thereby reducing overall cost.
[0234] The transmitter 210 may include a high voltage switch that
excites the transducer elements 200. Ideally, both positive and
negative voltages are available. Any available spectral shaping may
also be beneficial to optimizing the transmit pulse. The receiver
212 may include a preamplifier, filters, and other signal
conditioning circuits prior to digitization.
[0235] Both the transmitter 210 and receiver 212 have an optional
beamformer. The transmit beamformer 214 has only one delay profile
per transmit event whereas the receive beamformer 216 is digital
and allows beamforming at multiple depths. A memory device 218
stores the digitized signal from each transducer. The number of
signals stored per acquisition is equivalent to the number of
transducers in the device. The memory 218 may also save previous
reference frame information. The information from the electronic
compass 206 is also digitized for each acquisition and stored in
memory 218.
[0236] The CPU 220 orchestrates the timing throughout the system
and places the components in specific states. The CPU 220 also
executes the tracking algorithm.
[0237] FIG. 29 describes the process flow chart that may be used to
acquire a signal data sed estimate the motion. It is assumed that a
reference signal data set has been acquired. The process flow chart
can be split into two separate regions. The first is the
acquisition area and the second is the algorithm. When the process
is coded, a producer (acquisition)--consumer (calculation) model
may be used to limit complexity and optimize processing time.
[0238] On the acquisition side, the first step (block 250) is to
acquire the azimuth, elevation and roll angles from the electronic
compass. These angles are used to calculate the distance moved
relative to the current reference frame and ultimately the starting
location. It is beneficial to use averaging or other filtering
techniques that remove any acceleration componenta.
[0239] Next, at block 252, the signal vectors are acquired from the
transducers in either a pulse-echo or pitch-catch mode. It may be
necessary to reset the multiplexers depending on the system
hardware configuration for each transmit. Signal data may be
acquired at multiple locations or averaged to reduce phase error.
This step is repeated through decision block 254 until the signal
pulses from each transducer are acquired. In the embodiment
depicted in FIG. 29, the number of transducers is 3, however, more
transducers may be used since redundancy decreases the possibility
of error.
[0240] After the current signal vectors are acquired, the signal
vectors from the current referece frame are recalled from memory at
block 256 and passed to the RfUME (Radio Frequency Ultrasound
Motion Estimate) algorithm, which operates at block 258. The RfUME
algorithm finds the phase change between the current signal vectors
and the reference. A correlation technique such as sum of absolute
differences (SAD) may be used to find the best match for each
vector pair. This time difference is used in the RfUME algorithm to
calculate the total movement in x, y and z from the reference.
Along with the movement, the RfUME algorithm assesses the quality
of the fit. If SAD is used to determine the best fit, a higher SAD
value implies a lower quality fit. A histogram analysis of SAD
shows that the SAD magnitude predicts whether a motion estimate
from the RfUME algorithm is good or bad. For example, if the SAD
value is below a certain amount, then the measured phase difference
for that transducer is good. If it is above a certain amount, then
the measured phase difference may be good or bad. This SAD value is
defined as the critical SAD.
[0241] Therefore, after the RfUME algorithm calculates the motion,
the SAD values (one SAD value for each transducer) are also
compared to the critical SAD at decision block 260. If the SAD
values for any of the transducers are greater than the critical
SAD, then this result suggests that the previous signal acquisition
should have been the new reference. In this case, the previous
measured x, y and z location is the accumulated movement (block
262). In order to limit re-referencing which may accumulate a
significant amount of error, the accumulated x, y and z location of
the possible new reference is compared with all of the stored
references at decision block 264. If the accumulated x, y and z
position is near an old reference and the SAD values are
acceptable, then instead of using a new reference, an old reference
is used at block 266. This technique may be beneficial when trying
to hold the device still and re-referencing error must be
limited.
[0242] Regardless of whether a new reference or stored reference is
used, the RfUME algorithm may be used at block 268 to calculate the
movement and SAD values. Next, the SAD values may be compared to a
SAD threshold at decision block 270. This threshold is dependent on
the sample rate of the process flow chart as well as the user
model. For example, the higher the sample rate, the closer the SAD
threshold could be to the critical SAD value. Furthermore, the
faster a user might move given a fixed sample rate, then the lower
the SAD threshold. SAD threshold prevents loss of tracking ability
by updating the reference frame at an acceptable rate. Therefore,
if the SAD values are greater than the SAD threshold, the
calculated x, y and z location is the accumulated movement and the
current signal data becomes the new reference at block 272. Again,
to limit the amount of re-referencing, the accumulated x, y and z
position are compared to the stored reference positions at decision
block 274. If there is a close match and the SAD values are
acceptable, then the stored reference is used rather than the newly
acquired signal vectors at block 276.
[0243] After the critical SAD and threshold SAD are tested, the
amount of movement is compared to movement thresholds at decision
block 278. These thresholds for x, y and z are based on the
transducer position and performance. For example, the wider the
beam response for the individual transducers, the longer the
distances that can be tracked from the reference frame.
Furthermore, the directional matrix, frequency and bandwidth also
affect the tracking performance. If these movement thresholds are
exceeded, then the movement is accumulated and the reference
vectors are changed at block 272. This process continues until it
is no longer desired to track motion.
[0244] In the RfUME algorithm, the recursive solution is used to
track translation as well as rotation. In other words, movement
from the reference position includes both translation and rotation
(Equations 36a-36c). X.sub.total=X.sub.rotation+X.sub.translation
(36a) Y.sub.total=Y.sub.rotation+Y.sub.translation (36b)
Z.sub.total=Z.sub.rotation+Z.sub.translation (36c)
[0245] RfUME only tracks the movement from the current reference
frame. Therefore, it is possible to rotate between the current
reference frame and the old reference frame such that the
coordinate system axes are different. The electronic compass helps
account for this difference. The general equation is:
X.sub.i0=X.sub.k0+S.sub.k0.sup.-1X.sub.ik (37) where X.sub.i0 is
the distance from original reference to the current position,
X.sub.k0 is accumulated distance from the original reference to the
current reference, S.sub.k0 is the rotation matrix (3.times.3)
between the current reference and the original reference, X.sub.ik
is the distance measured with the RfUME algorithm from the current
reference to the current sample. The rotation matrix is determined
by the electronic compass and calibration to the ultrasound
transducer is required. In order to display the net movement,
X.sub.i0 must be multiplied by the negative of S.sub.i0, which is
the rotation matrix between the current sample and the original
reference.
[0246] It is also possible to obtain the azimuth, elevation and
roll angles with the RfUME algorithm. This is accomplished by
calculating the distance from multiple points in tissue. For
example, if multiple points are tracked along the z-axis for the
transducer concept depicted in FIG. 28, then the tip and tilt can
be determined. Azimuth may be determined by tracking multiple
points in a plane parallel to the transducer face.
[0247] Returning to the discussion of the flowchart in FIG. 5,
after initiating station keeping, the targeting catheter may be
withdrawn at block 112. As previously noted, acoustic arterial
hemostasis is more effective without the presence of a catheter,
guidewire or other structure present at the arteriotomy. Thus, the
targeting catheter 32 may be completely withdrawn from the patient
as illustrated in FIG. 7G while the user keeps the compression of
the therapeutic applicator 20 constant and keeps the arteriotomy 30
targeted within the focus of the therapeutic applicator 20 via
station keeping. The user interface on the applicator 20 may
provide feedback to the user to aid in maintaining optimal
compression and station keeping.
[0248] Finally, at block 114 of the flow chart in FIG. 5,
therapeutic energy may be applied from the applicator to cause
hemostasis. The treatment depth and dose may be automatically
calculated and administered after hemostatic compression and
arteriotomy targeting are achieved and the targeting catheter has
been withdrawn. FIG. 7H illustrates an energized ultrasonic
therapeutic applicator 20 delivering a focused ultrasound beam near
the arteriotomy 30. The partial absorbance of the ultrasound energy
by the tissue 31 at the focus of the beam causes rapid heating of
the tissue 31 near the arteriotomy 30. Without being bound by any
particular theory or mode of action, it is believed that the heat
denatures the native perivascular collagen with subsequent
formation of an extensive fibrin network that covers the
arteriotomy 30, thereby sealing it closed. The duration of therapy
may be any suitable period sufficient to effect hemostasis. In some
embodiments, a continuous application of therapeutic energy is
used. In other embodiments, the application of therapeutic energy
may be interrupted, for example to allow interim cooling or
repositioning of the therapeutic energy applicator 20. The
ultrasound treatment dose in one embodiment takes approximately 60
seconds.
[0249] As depicted in FIG. 30, during this dosing period, the user
interface located on the therapeutic applicator may display
relevant information such as the amount of compression 300, a
targeting display 302 for keeping the ultrasound focused on the
arteriotomy, as well as a count down clock 304 indicating when
treatment will terminate. Upon completion of the dosing, a short
period of tissue cooling may be allowed to occur without
compression or applicator position being changed. Subsequently, the
treatment may be concluded by the therapeutic applicator being
removed from the patient's skin.
[0250] As described above, the targeting catheter may be used to
locate the precise position of the arteriotomy, such as by use of a
targeting aid (e.g., an inflatable balloon) located on the
targeting catheter. As note above, suitable targeting aids are not
limited to balloons but may include one or more arteriotomy
locating sensor(s). Suitable arteriotomy locating sensor(s) include
but are not limited to: i) acoustic transceivers capable of
transmitting and receiving acoustic signals (such as Doppler), ii)
self-heated thermistor-based probes for detecting the arteriotomy
location by discriminating conductive and convective energy
dissipation levels in the tissues and blood surrounding the probe,
and iii) use of piezoelectric materials self heating
characteristics to discriminate conductive and convective energy
dissipation levels in tissues and blood surrounding the probe.
Additional descriptions for these three arteriotomy detection
techniques are provided below. Those of skill in the art will
appreciate many other possible methods and sensors for determining
whether a sensor (or arbitrary location on a catheter) is located
within a blood vessel versus or within tissue.
[0251] One example of arteriotomy locating sensor(s) includes one
or more Doppler transducers as illustrated in the targeting
catheter 310 depicted in FIG. 31. This targeting catheter 310 has a
soft flexible tip 312 with one or more locating and targeting
piezoelectric Doppler devices 314. Further up the catheter 310 is a
Doppler compression sensor 316 and a hub 318 located at the
terminal end of the catheter 310. Within the hub 318 is a tuning
(matching) circuit and a mechanical and electrical connector
allowing the targeting catheter 310 to be mechanically and
electrically connected to the control system hardware.
[0252] The arteriotomy localization step may be accomplished by
slowly withdrawing the targeting catheter, thereby causing the
arteriotomy locating sensor(s) (e.g., Doppler devices 314) to get
closer to the arteriotomy. The sensor signal is monitored to
determine when the arteriotomy locating sensor is proximate to the
arteriotomy. In one embodiment, the Doppler transducer(s) 314 may
also emit an ultrasound signal which is received by ultrasound
receivers or transducers located on the applicator to monitor the
movement and position of the Doppler transducer(s) 314, such as by
using ATOF as described above.
[0253] FIG. 32 is a schematic illustrating one embodiment of a
procedure that may be used for arteriotomy localization (AL) using
the catheter depicted in FIG. 31. In this illustration, the Doppler
transducer is referred to as a "CW beacon." In one embodiment, the
targeting catheter 310 has a flexible construction to minimally
distort the vessel position relative to the therapeutic applicator
during targeting. Thus, in one embodiment, as depicted in FIG. 31,
it is preferred that the AL positioning is accomplished only
through pulling (i.e., not pushing). This pulling may be
accomplished by a withdrawal motion using either continuous
movement or discrete incremental pulls. Pulling may be accomplished
through either a manual process or by a device implementing a
controlled pull process of the targeting catheter 310. The speed
and force associated with the targeting catheter 310 withdrawal
maneuver to achieve the AL position may allow for clinically
practical manual dexterity and a reasonable time for AL
positioning, especially when using manual pulling. In one
embodiment AL position takes only several seconds. In an
alternative embodiment, a targeting catheter 310 may be used that
is stiff enough to be both pushed and pulled into the arteriotomy
locating position.
[0254] To guide the user to achieve accurate arteriotomy
localization placement, specific vascular locations may be detected
by the arteriotomy location sensor (e.g., Doppler transducer(s))
using an algorithm subsystem. Upon detection, this information may
be translated into feedback presented to the user through the user
interface located on the display of the handheld therapeutic
applicator. In one embodiment, depicted in FIGS. 33A-33C, a "Green
Light/Yellow Light/Red Light" display may be utilized. After the
targeting catheter has initially begun to be withdrawn, the
arteriotomy locating subsystem can detect the arteriotomy locating
sensor (e.g., Doppler transducer(s)) passing into the "treatment
volume," defined approximately by the tissue cylinder having as
it's top surface the footprint of the therapeutic applicator. At
this point, the user interface may display a "Green Light" (FIG.
33A) to indicate to the user that the beacon has crossed into the
treatment region. While the user is pulling in the "Green Light"
state, the pull velocity can be monitored via ATOF and, via
communication with the ATOF system, the AL algorithms can detect
beacon withdrawal velocities that may be too high (e.g., >3
mm/sec). Upon exceeding this velocity limit, the AL algorithm can
trigger the user interface to alert the user to slow down the
withdrawal speed if the user is using manual pulling. Once the AL
subsystem detects the arteriotomy location sensor (e.g., Doppler
transducer(s)) as having reached an arteriotomy "proximity zone",
defined, for example, as 8 mm from the arteriotomy along the
targeting catheter track, the status light will change to "Yellow"
on the user interface to alert the user to slow down the withdrawal
speed, as shown in FIG. 33B. The ATOF system can be used to monitor
the withdrawal speed and alert the user to slow down if the speed
exceeds an appropriate value relevant to the proximity zone, for
example, 1.5 mm/sec. Once the AL subsystem detects the arteriotomy
location sensor(s) (e.g., Doppler transducer(s)) as having achieved
arteriotomy localization (the "AL Position"), defined as a position
at or a known distance from the centroid of the arteriotomy, with a
tolerance on positioning of +/-1.0 mm, the status light will change
to "Red" on the user interface (as shown in FIG. 33C) to alert the
user or a targeting catheter puller device to stop the withdrawal
of the targeting catheter.
[0255] Those of skill in the art will appreciate that other methods
of providing feedback to a user to adjust the speed of catheter
withdrawal may be used. For example, the actual rate of withdrawal
may be displayed to the user. In addition, audible signals may
employed such as tones or voice commands.
[0256] FIG. 34 is a schematic depicting the withdrawal of the
targeting catheter 310. The spatial relationship of the arteriotomy
locating sensor 322 (e.g., Doppler transducer(s)) relative to the
arteriotomy when at the arteriotomy localization position can be
described by the distance vector, L.sub.btis, that describes the
distance between the arteriotomy locating sensor 322 and the
centroid 324 of the puncture site along the path of the targeting
catheter and puncture track as shown in FIG. 34. The centroid 324
of the arteriotomy is defined as the intersection of the targeting
catheter 310 axis and the middle of the femoral artery wall at the
puncture. If L.sub.btis has a positive value, the arteriotomy
locating sensor 322 (e.g., Doppler transducer(s)) is positioned in
the tissue track, whereas, if L.sub.btis is negative the
arteriotomy locating sensor 322 (e.g., Doppler transducer(s)) is
within the artery lumen. If L.sub.btis=0.0 the arteriotomy locating
sensor 322 (e.g., Doppler transducer(s)) resides precisely at the
centroid 324 of the puncture site.
[0257] As shown in FIGS. 32 and 34, the arteriotomy locating sensor
may include an acoustic transducer labeled "CW Beacon" 322. The
localization step may be accomplished by using the beacon 322
Doppler shift signals, as processed and interpreted by the
arteriotomy localization hardware/software (a combination of system
hardware and system software incorporating arterial localization
specific algorithms). The "CW Beacon" 322 may transmit an acoustic
signal and detect the Doppler shifted echo. The Doppler shift
information is associated with motion at and near the arteriotomy,
and the dominant motions yielding beacon 322 position-relevant
signal information are those associated with blood flow (e.g.,
velocity, flow turbulence, blood flow direction relative to the
beacon 322 orientation, and blood pressure variations). The Doppler
processing used can either be based on non-directional or
directional (In-Phase and Quadrature) modes. In addition, different
frequencies can be used to excite different beacon 322 vibrational
modes, modifying the tissue and spaces interrogated for Doppler
shift information.
[0258] Although it is anticipated that the Doppler signals of
relevance will occur in the audible portion of the spectrum, in one
embodiment, the electronic system user interface is able to inform
and guide the user as to beacon 322 localization through either
audible or non-audible (principally visual) cues. In this way, less
user training and experience will be required to achieve reliable
arteriotomy localization. Localization cues that are non-audible
and thus not dependent on a user learning "targeting sounds" may be
generated by having the Doppler signals be processed by the
arteriotomy localization hardware/software in a manner which can
identify the acoustic signature of the arteriotomy or other
characteristic location near the arteriotomy that has a consistent
and unique acoustic signature.
[0259] FIG. 35 displays one embodiment of a system that may be used
for targeting catheter placement. A targeting catheter transducer
("TA TXCR") 324 may be mounted on the targeting catheter.
Ultrasonic send and receive circuits ("T/R") 326 and processing may
be provided by programmable pulser 328, amplifier 330, and analog
to digital converter 332, through transmit/receive switch 326--all
under control of a processor 334, which itself is capable of either
CW or pulse wave Doppler processing (depending upon the
embodiment). This exemplary processing configuration will be used
as the basis for describing several approaches to targeting
catheter placement below. Each approach to targeting catheter
placement generally follows a process wherein the operator advances
the targeting catheter into the body via an introducer sheath or
entry channel and positions it in the entry channel in response to
user interface information.
[0260] Forward looking Doppler--FIG. 36 depicts the functionality
of a technique employing forward looking pulsed wave Doppler to
measure the distance 340 in front of the targeting catheter beacon
178 at which the arterial flow volume is located. Here, beacon 178
is pulsed at a relatively high (approximately in the range 3-8 MHz)
frequency, projecting a narrow acoustic beam 198 axially and in
front of beacon 178. The beacon 178 detects the Doppler shifted
echo of each pulse. The computer of FIG. 35 executes range-gated
analysis of the Doppler pulse, thus measuring distance to the
region of blood flow, 340. The user interface can instruct the
operator to position the beacon 178 at a point corresponding to the
clearance location (CL), the place where the beacon 178 is located
outside of the region of insonification from the therapy beam.
Accordingly, in some embodiments, the targeting beacon 178 may
remain in the body during application of therapy, providing desired
targeting information to a user to assist the user in maintaining
the focal point of the therapeutic energy at the site of the
arteriotomy 30. For example, the location of the beacon 178
relative to the therapeutic applicator 20 along with the distance
to flow volume 340 may be used to determine the location of the
arteriotomy 30 relative to the applicator 20.
[0261] Alternatively, in systems with two (or more) beacons 178
located on the targeting catheter, the geometric uncertainty
created by stick angle variation may be compensated for, assuming
that an ATOF positioning system is in operation during the
targeting catheter placement and location process. For example,
referring to FIG. 36, the forward looking Doppler distance desired
for proper positioning is defined by: DISTANCE TO FLOW
VOLUME=(V+Dw+F)/sin (alpha s) Eq. 38
[0262] Side-looking Doppler--FIG. 37 illustrates another
positioning alternative wherein pulsed wave Doppler transmitted in
a beam 342 perpendicularly to the axis of the targeting catheter 32
locates the flow volume. In a manner similar to that employed in
the forward looking Doppler technique, measurement of the distance
to the flow volume 344 is made and is used as a parametric
representation of the location of beacon 178 with respect to the
Arteriotomy 30.
[0263] Z matching--In yet another alternative method illustrated in
FIG. 38, a technique is used which locates the beacon 178 relative
to the arteriotomy 30 by matching the z coordinate (depth from the
applicator 20 surface positioned on the skin) of the beacon 178 to
the z coordinate of the flow volume: Z FLOW VOLUME+DELTA=Z TA Eq.
39 where DELTA is an offset value representing the distance above
the flow volume desired for beacon positioning.
[0264] In this approach, the z coordinate of the beacon 178 is
measured by utilizing the ATOF triangulation system--TOF distances
180 between the beacon 178 and the receiving sensors 171 on the
applicator 20. The z coordinate of the anterior surface of the flow
volume (shallowest) is measured, as depicted in FIG. 38, by pulsed
Doppler ranging with pulses transmitted by the therapeutic array in
applicator 20 and received by beacon 178. Because the therapeutic
transducer may normally operate at a small f/number, an
interrogating Doppler line could be constructed from a number of
transmit pulses having progressively varying focal positions. This
method offers very high resolution location of the flow volume due
to power available and the sharp focus.
[0265] In this technique, the applicator 20 would ideally be in
targeted position when executing the Z matching because the artery
28 may be deep at various positions. An iterative method of
positioning may be used wherein the applicator 20 is approximately
positioned, beacon 178 is placed, and then the applicator 20 and
beacon 178 are re-positioned for final targeting.
[0266] Those of skill in the art will appreciate several
alternative approaches for utilizing a targeting catheter beacon
178 in combination with the sensors 171 on the therapeutic
applicator 20. For example, in one embodiment, a separate Doppler
transducer (one or more channels) may be integrated into the
applicator 20 face and used to both send and receive.
[0267] Combination Methods--It is noted that the above methods may
advantageously also be used in combinations with each other, for
example, by combining forward looking and side-looking Doppler.
Such combinations may be used to increase robustness of the
positioning process. These methods may also be used in combination
with thermal methods. It is noted that beacons on the targeting
catheter may be used to make self-heated thermal measurement and
associated position determinations inside or outside of flowing
blood. In this method, the capacitance may be measured at an off
resonant frequency of the piezoelectric material (e.g. PZT) to
estimate temperature.
[0268] In some embodiments, the arteriotomy location sensor on the
targeting catheter may be a thermistor based probe, used either
alone or in combination with an ultrasound transducer. Use of
self-heating thermistors is termed herein as Thermistor Detection
via Targeting and Monitoring (TDTM). These probes contain
thermistors as sensors to assist in locating the puncture site,
monitoring leakage of fluids or bleeding (prior to and during
treatment), confirming the targeted location of the therapeutic
energy delivery, and measuring and monitoring at least a portion of
the thermal dose delivered to the treatment field. In order to be
inserted down the puncture track, and thus directly into the
puncture wound at the vessel or body cavity, the TDTM probes may
have physical structures, and sizes, similar to catheterization
guidewires. They can be deployed as an integral portion of a
therapeutic hemostasis procedure using either non-invasive or
invasive therapeutic heating modalities, and have the advantage of
requiring little additional effort or complexity in the puncture
sealing or closure procedure.
[0269] The core sensor(s) deployed on the TDTM probes may be one or
more thermistors (temperature sensors possessing the property of
electrical resistance that varies with temperature). Both the
electrical resistance variation with temperature of thermistors and
their property of self-heating when supplied with adequate
electrical power may be utilized. The latter property refers to the
fact that when a thermistor is connected to an electrical circuit,
power is dissipated in it as heat and, thus, the body temperature
of the thermistor rises above the temperature of its immediate
environment. An energy balance on the thermistor requires that the
rate at which energy is supplied (Q.sub.s) must equal the rate at
which energy is lost, plus the rate at which energy is absorbed
(energy storage). The rate of thermal energy delivered to the
thermistor is equivalent to its electrical power dissipation, i.e.,
Q.sub.s=P=I.sup.2R=VI. The rate at which a thermistor's thermal
energy is lost to its surroundings (Q.sub.L) is proportional to the
temperature difference between it and its surroundings, i.e.,
Q.sub.L=.delta.(T-T.sub.a), where .delta. is the "dissipation
coefficient." The dissipation coefficient is defined as the ratio,
at a specified temperature, of a change in the power dissipation of
the thermistor to the resultant thermistor body temperature change.
The dissipation constant depends on the thermal environment around
the thermistor, so naturally, the coefficient depends on the
thermal conductivity of the medium surrounding it, convection
(forced or free convection) influences, as may result from relative
motion between the surrounding medium and the thermistor, and
thermal conduction through leads and surfaces upon which the
thermistor is mounted, etc. The dissipation coefficient is also
naturally dependent upon the physical geometry of the thermistor,
especially its surface area and mass. For example, a larger surface
area will result in a larger dissipation coefficient for a given
thermal environment. This in turn requires more input power for a
larger thermistor than a smaller one in order to achieve an
equivalent temperature difference between the thermistor and its
surroundings. The additional power requirement effectively reduces
the sensitivity of the device. Furthermore, a small thermistor
device will have low thermal mass, which will allow it to cool and
re-heat relatively quickly. This relatively fast thermal response
makes the smaller device more sensitive to rapid changes in the
dissipation coefficient.
[0270] It has been found that small self-heating thermistors, when
placed in the human body in medical procedures, can be used to
measure tissue temperature, thermal properties, blood temperatures
and, when appropriately calibrated, even blood flow levels in
organs and vessels. Similar principles may be applied in detecting
and discriminating levels of blood flow at and surrounding the
puncture wound site, and in discriminating conduction and
convective energy dissipation levels in the tissues surrounding the
probe. The TDTM probe may be positioned in the tissue such that its
thermistor sensor(s) can travel to and be located in close
proximity to the puncture site, typically through the puncture
track created by the instrument producing the puncture wound and/or
maintaining the wound portal open (e.g., a catheter or needle).
[0271] FIG. 39 illustrates a TDTM probe having a single
self-heating thermistor 414 at the tip of the targeting catheter 32
inserted into an agar tissue phantom 418 incorporating a "blood
vessel" 412 (duct cast into the agar) perfused with a
blood-mimicking fluid (e.g., water in thermal equilibrium with the
agar) 410.
[0272] The probe 414 may be placed in the vessel 412 in a manner
analogous to arterial catheterization, by creating a puncture track
from the "skin" surface down to the vessel puncture site
(intersection of the probe 414 with the vessel 412). By moving the
probe 414 (probe) 414 travel is indicated as by arrows 416) in the
puncture track, such that the sensor 414 (e.g., the thermistor
bead) can be alternatively placed a) in the track, b) at the
anterior (upper) vessel wall (i.e., the puncture site) or c) in the
lumen of the vessel 412, thermistor signals indicative of the bead
location are provided as output to the data acquisition system.
[0273] FIG. 40 is a graph of temperature differential, show the
variation of the differential for various locations of the probe.
The thermistor may be first "zeroed" with the bead in the track
(i.e., the equilibrium temperature whereby the self-heated
thermistor is in the track and has no flow may be set as the
baseline). After zeroing, maneuvering the probe in and out of the
"vessel" will produce characteristic thermal signals indicative of
the bead position. For example, as the probe bead is advanced into
the lumen of the vessel, the sensor signal indicates the associated
cooling signature due to heat dissipation into the blood flow (bead
temperature decrease with characteristic flow-perturbation jitter
in the temperature waveform). Subsequently, a withdrawal movement
of the bead back toward the skin, pausing at the anterior (upper)
wall, indicates an increased signal (higher temperature) associated
with less efficient cooling due to the flow boundary layer at the
vessel wall. In turn, as the probe is further withdrawn and the
bead is returned to a position just in the track (2 mm out of the
lumem), the characteristic relatively unperturbed temperature
baseline waveform is again reproduced. Accordingly, the thermistor
sensor has the ability to indicate when it is, alternatively, in
the track (here above the vessel), in the lumen of the vessel, or
at the wall of
[0274] The thermistor also has the ability to indicate when
bleeding in the track occurs. FIG. 41 depicts a graph where blood
mimicking flow (using water) is produced over the thermistor one
drop at a time while the bead is in a track (small duct in thermal
equilibrium with the agar and the fluid). As can be seen, the
thermistor signal is extremely sensitive to detecting even discrete
drops flowing over it. Thus, in principle, a TDTM probe having a
thermistor bead in its shaft in the puncture track should be
sensitive enough to detect any thermally significant track
bleeding, or bodily fluid leakage, from the puncture site.
[0275] When used in patients, the nature of the thermistor
temperature signals will change relative to the above results in
phantoms, in large part due to the pulsatile nature of blood flow
in arteries and veins. To characterize TDTM probe behavior under
such conditions, arterial catheterization wounds in pigs were
studied. FIG. 42 shows the experimental setup with the artery 412
located in the pig tissue 420 and the vessel puncture site situated
at 414, again using the single bead TDTM probe of FIGS. 39 through
41.
[0276] As shown in the graphs depicted in FIGS. 43A and 43B, when a
thermistor bead is fully in the artery luminal blood flow, an
oscillatory thermal signal is produced of significant amplitude,
indicative of the pulsatile change in convective cooling
surrounding the bead, i.e., the stop-start nature of the vessel
blood flow accompanying the heart cycle (systole to diastole) of
the animal. As the tip of the probe is drawn up to the anterior
(upper) vessel wall and into the puncture wound in the vessel, the
magnitude of the signal increases (more heating occurs), but the
oscillation amplitude is diminished, both trends associated with
decreasing flow velocity next to the artery wall (poorer cooling
due to the wall boundary layer flow, exhibiting less flow
fluctuation from systole to diastole) (see FIG. 43A). While
translating the probe tip up into the track just above the vessel
wall, some pulsatile flow cooling is still present in the
experiment, here due to only minimal tissue compression being
applied at this time. FIG. 43A indicates, however, that the event
of compressing the tissue maximally (to the point where no bleeding
occurs in the track) can be faithfully reflected in the thermistor
signal, as the equilibrium temperature rises to a maximum
(conduction dominated thermal equilibrium normally associated with
the baseline zero temperature) and pulsatile oscillations (due to
track convection) are extinguished.
[0277] Thus, TDTM probe thermistor beads can provide signal
information indicating when they reside either in the lumen of the
vessel, near or at the vessel wall, or in the track, with either
modest or significant compression (i.e., indicating the presence or
absence of track bleeding). These properties can therefore be used
to both place a TDTM probe in the track such that the probe would
be in a known relationship to the puncture site, and in such a way
that track bleeding could be monitored, providing user feedback on
level of tissue compression, with such information also being used
to confirm absence of track bleeding, avoiding potentially
compromising the efficacy of the cautery thermal dose via heat
carried away in blood from the treatment zone.
[0278] As will be described below, the ability of placing the TDTM
probe 428 in fixed relationship to the puncture site can be useful
in targeting the therapeutic energy from a device used for deep
cautery. One method to place the probe at the puncture site is
illustrated in FIG. 44 using a TDTM probe with two thermistor beads
430 and 432. Here the probe 428 is placed such that its distal end
beads 430 and 432 (separated by a small distance optimized for the
application) straddle the puncture hole. In this case, the distal
sensor 430 resides in the lumen of the artery 28, whereas the
proximal bead 432 is in the track just above the puncture. The
signals from the thermistors can be such that they can guide the
clinician in positioning the probe 428 in this arrangement at the
puncture. The guidance in such positioning could be derived from
either direct operator observation and interpretation of the
waveforms, or through a more automated, yet simple, user interface
(e.g., one employing an algorithm that translates the waveform
information into automatically interpreted symbolic information
providing positioning cues).
[0279] FIG. 45 is a graph depicting sample temperature traces from
an in vivo pig experiment in which successful placement of the
thermistor bead portion of the probe was placed in the artery in
the arrangement represented in FIG. 44, i.e., dual beads were
positioned to straddle the femoral artery puncture.
[0280] Another embodiment includes a triple bead TDTM probe, as
shown in FIG. 46. In this embodiment, similar to FIG. 44, the
distal bead 430 (nearest the tip) would be placed in the lumen of
the punctured vessel 28, while the proximal bead 432 is placed in
the puncture track, thus bracketing the puncture site. In this
case, assuming bead separation distances optimized to the
application, the third (center) bead 434 may be located
approximately at the puncture site. Deployed in this fashion, the
thermistor beads could be used for guiding and confirming the
placement of the therapeutic energy dose, for example, by simply
delivering test exposures (shots) of therapeutic energy at the
appropriate depth and positioning the therapeutic beam using the
feedback of the thermistor heating responses to maximize the
heating response on the center bead. Those of skill in the art will
appreciate that any number of thermistors may be employed to
provide further precision in locating an arteriotomy.
[0281] To illustrate one method for guiding a therapeutic beam for
targeting, FIG. 47 is graph showing the thermal responses from a
dual bead TDTM probe placed at the puncture site as in the case
shown in FIG. 44, here in a pig femoral artery subjected to pulsed
test shots of therapeutic energy. The position of the beam focus
and the probe thermistor beads are simultaneously monitored using
gray scale B-mode (2D) ultrasound imaging. As shown, while using
controlled movement of the hand-held therapeutic applicator, the
position of the focus of the therapeutic beam passes (in the plane
of the 2D image) from bead #1 to bead #2. The path of the
therapeutic beam focus is reflected in changes in amplitude of the
temperature spikes produced by the pulsed delivery of power as the
applicator targeting orientation and position is moved. By
maximizing the temperature spike at the bead designated as the
target sensor, the energy can be appropriately targeted (while the
TDTM probe is in place in the tissue puncture region).
[0282] In some embodiments, attempts to seal the puncture with the
TDTM probe in place (i.e., deployed through the puncture) is
contraindicated due to the tendency of the probe to either a)
interfere with the sealing process during dosing, or b) disrupt a
successful seal upon removal of the probe. Accordingly, in some
embodiments, the probe is at least partially withdrawn until it is
clear of the puncture prior to the delivery of the dose. This
maneuver will not eliminate the advantages of the probe. While in
situ (at the puncture), the TDTM probe can be used to position the
therapeutic beam at the puncture, as described above. Further, the
adequacy and level of the therapeutic dosing power can be assessed
through the thermistor thermal signals in response to test power
pulses (as illustrated in FIG. 47) while the probe is in place
prior to dosing. Additionally, by withdrawing the TDTM probe just
prior to dosing sufficiently to clear it from the puncture site,
but with at least one thermistor remaining in the puncture track,
the probe can be used to monitor and guide compression and confirm
the absence of track bleeding.
[0283] It is also possible to use TDTM probe thermistors in
conjunction with other sensors (non-thermistor) for targeting and
monitoring the puncture site. These "partner" sensors could be
deployed on the shaft of the probe used in the puncture track, and
could provide complementary, redundant or unique information for
orienting and guiding a medical device of interest (e.g., a
therapeutic device such as an ultrasound applicator used for
sealing puncture wounds). FIG. 48 illustrates a system where the
probe contains two thermisters and one non-thermister partner
sensor positioned in between. An example of complementary
information from the thermistor could include monitoring the state
of bleeding of the puncture track, while the partner sensor
broadcasts its location for 3D positioning (e.g., by a distance
measurement-based or time-of-flight based triangulation method with
appropriate receiver-transmitter pairs, such as the ATOF technique
described in above). Such partner sensors could be based on a
variety of energy forms, such as electrical, electromagnetic,
magnetic, and acoustic energy, using appropriate transmission and
receiver modules in the sensor and on the medical device being
guided.
[0284] In some embodiments, a TDTM probe is used in conjunction
with invasive therapeutic devices used for sealing puncture wounds.
FIG. 49 illustrates a system where both thermister beads and a
therapeutic heat source are introduced to the puncture site. Such
therapeutic heating devices could be placed down the puncture
track, deployed as catheter-like minimally invasive surgical (MIS)
tools, and could have their sources of thermal energy delivery
(therapeutic head) located at their distal tip. A variety of energy
sources could be possible with such MIS tools (e.g., RF electrical
heating devices, therapeutic laser energy delivered via
fiber-optics or light wave-guides, microwave antennae, ultrasound
transducers, and the like). As for non-invasive hemostasis
applicators, the invasive therapeutic devices can be positioned in
appropriate relation to the puncture site to effectively target and
seal the wound. The TDTM probe could be used to locate the
therapeutic head of the invasive sealing device at the puncture
site by using the TDTM probe as a guide-wire structure. In this
configuration, the thermistor beads of the TDTM probe would be
placed at the puncture site, with the cautery device deployed over
the TDTM probe and advanced toward the puncture site until it
reached a position that corresponded to an appropriate separation
distance between the therapeutic head and the puncture site. Prior
to delivering the thermal dose, the TDTM probe could be withdrawn
like a guidewire up into the inner channel of the cautery probe to
remove the thermistor beads from the heated treatment zone before
the thermal dose is delivered to the puncture site. As for the
previously described TDTM probe concepts, the thermistor beads
could also be used to confirm adequate compression at the treated
site by monitoring bleeding up the track of the MIS cautery device.
In addition, the thermistor beads could be used to monitor the
level of the delivered dose through the thermal response of the
thermistor to therapeutic test doses, as describe above.
[0285] In summary, the TDTM probe can be used in conjunction with
both non-invasive and invasive thermal sealing or cautery
therapeutic devices in halting bleeding or bodily fluid leakage at
depth from penetration wounds associated with medical procedures.
The TDTM probe can assist in: a) locating the puncture site (e.g.,
arteriotomy), and can be positioned in relationship to this site;
b) confirming/guiding tissue compression levels adequate to
eliminate track bleeding during application of the thermal dose;
and c) targeting the therapeutic energy; d) assessing in situ the
propriety of the therapeutic power In addition, the thermistor
sensors can be used in combination and coordination with other
types of sensors, and in different configurations and spatial
arrangements. Further more, the thermistor sensors can also be used
to guide invasive therapeutic devices (e.g., minimally invasive
surgical type tools). Finally, TDTM probes with one, two, three or
more sensors can be used, depending on the application and the
procedural approach desired.
[0286] Although the invention has been described with reference to
embodiments and examples, it should be understood that numerous and
various modifications can be made without departing from the spirit
of the invention. Accordingly, the invention is limited only by the
following claims.
* * * * *